<SEC-DOCUMENT>0001213900-22-021801.txt : 20220427
<SEC-HEADER>0001213900-22-021801.hdr.sgml : 20220427
<ACCEPTANCE-DATETIME>20220427090040
ACCESSION NUMBER:		0001213900-22-021801
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220427
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220427
DATE AS OF CHANGE:		20220427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		22856550

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea158566-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ABVC="http://abvcpharma.com/20220427">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_ABVC_abvcpharma.com_20220427 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220427_20220427 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20220427.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-27to2022-04-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-27</xbrli:startDate>
        <xbrli:endDate>2022-04-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_906_edei--DocumentType_c20220427__20220427_zxMjonGqJlE7"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_90D_edei--DocumentPeriodEndDate_c20220427__20220427_zpyt7s0dbbLf"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April 27, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20220427__20220427_zDs0P9185iMl"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220427__20220427_zlXLcTBXdHQ2"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityFileNumber_c20220427__20220427_zefGvhRHcwwi"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityFileNumber">333-91436</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220427__20220427_zidrbTWYJ7s9"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction<br />
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20220427__20220427_zYqb6eiwJY46"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20220427__20220427_zEaNeZXWStSl"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20220427__20220427_zhXPVx3yMUQ1"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric> </span></b></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityAddressPostalZipCode_c20220427__20220427_zE3Lfde1Coj1"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: <b>(<span id="xdx_901_edei--CityAreaCode_c20220427__20220427_zZQgpMNib08"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_903_edei--LocalPhoneNumber_c20220427__20220427_zKFQch18bpHl"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--WrittenCommunications_c20220427__20220427_zJlHK40FDwra"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--SolicitingMaterial_c20220427__20220427_zXsI3qzBIGag"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20220427__20220427_zP6CWjFLm744"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20220427__20220427_zCLZk6OlXBi9"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif">Title of Each Class</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif">Trading Symbol</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--Security12bTitle_c20220427__20220427_zon91xLZhHk4"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--TradingSymbol_c20220427__20220427_zRJ823PKZXj6"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">The <span id="xdx_90A_edei--SecurityExchangeName_c20220427__20220427_zA6bN7V52Cnf"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;<span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20220427__20220427_zcgOwWUyLPv4"><ix:nonNumeric contextRef="From2022-04-27to2022-04-27" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01: Regulation FD Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On or about April 27, 2022, ABVC BioPharma, Inc.
(the &#8220;Company&#8221;) starts mailing a notice to its shareholders regarding the Company&#8217;s upcoming annual shareholder meeting.
The shareholder meeting will be held on May 20, 2022 at 9:00 p.m., local time in Taiwan (or 9:00 a.m. EST), as a virtual electronic meeting
using a Zoom video webinar (the &#8220;Meeting&#8221;). Due to concerns regarding the coronavirus pandemic and to assist in protecting
the well-being and health of its shareholders and employees, the Meeting will be held virtually via the Internet only with no physical
in-person meeting excluding the Board of Directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>To attend the virtual Meeting, go to the Zoom
link below:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">https://us06web.zoom.us/webinar/register/WN_N4Og75-7SC-D69RZENZRMg</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Meeting will be held for the purpose of considering
and voting upon several proposals, as set forth in the notice, which is attached hereto as Exhibit 99.1</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The notice
and related proxy card will be mailed to each shareholder entitled to vote at the annual meeting. Shareholders are urged to read the entire
notice as it contains important information about the proposed corporate actions. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the annual meeting, the Company will file
an amendment to this Report to disclose the voting results.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in Item 7.01 is intended
to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the&#160;Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the&#160;Exchange Act, except as
expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statement and Exhibits </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea158566ex99-1_abvcbio.htm">Notice to Shareholders</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea158566ex99-2_abvcbio.htm">Form of Proxy Card</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>104 </td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 27, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Howard Doong</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard Doong</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5ltpEBemnRUWsIkXE32C3EmyzZROrHslbGlvEZWFZZt6MECOxppWpkeG8KHI4YtPW2iMUWCGjvWBwZJttCuEWeDXOs7a+f39gRoHBwMxiOdFB6K2dcVimkEzHcj5WCqRKkxkcdiL66hnZypRovdE1aFvCgallg17za0g46idZal591QnZGbIpyDgZ5DeoRCrYU6cfxDcHeZ6JaNRPJNZM9/Zbc3eeGljW2IQuN6D/jT4X0klJ -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea158566ex99-1_abvcbio.htm
<DESCRIPTION>NOTICE TO SHAREHOLDERS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABVC
BIOPHARMA, INC. &nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>44370
Old Warm Springs Blvd., Fremont, CA 94538</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF 2022 ANNUAL MEETING OF SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders of ABVC BioPharma, Inc.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are cordially invited to attend the 2022 annual shareholder meeting of ABVC BioPharma, Inc. (the &ldquo;Company&rdquo; or &ldquo;ABVC&rdquo;)
to be held on May 20, 2022 at 9:00 p.m., local time in Taiwan (or 9:00 a.m. EST), as a virtual electronic meeting using a Zoom video
webinar (the &ldquo;Meeting&rdquo;). Due to concerns regarding the coronavirus pandemic and to assist in protecting the well-being and
health of our shareholders and employees, the Meeting will be held virtually via the Internet only with no physical in-person meeting
excluding the Board of Directors. Technology will be incorporated into the Meeting to increase efficiency, allow for social distancing
and provide for shareholder participation. In addition to on-line attendance, shareholders can hear all portions of the Meeting, submit
written questions during the Meeting and listen to live responses to shareholder questions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
attend the virtual Meeting, go to the Zoom link below:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://us06web.zoom.us/webinar/register/WN_N4Og75-7SC-D69RZENZRMg</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
you register with your name and email address, so that we can log attendees, you will be taken into the waiting room until the meeting
begins.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement is furnished in connection with the solicitation of proxies by the Board of Directors (the&nbsp;<B><I>&ldquo;Board&rdquo;&nbsp;</I></B>)
of ABVC BioPharma, Inc. (the&nbsp;<B><I>&ldquo;Company&rdquo;</I></B>&nbsp;) for use at the 2022 annual meeting of Shareholders of the
Company (the&nbsp;<B><I>&ldquo;Meeting&rdquo;</I></B>&nbsp;) and at all adjournments and postponements thereof. The Meeting will be held
on May 20, 2022, at 9:00 p.m., local time in Taiwan (or 9:00 a.m. EST), to consider and vote upon the following proposals:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To re-elect Eugene Jiang,
    Dr. T.S. Jiang, Dr. Tsang Ming Jiang, Norimi Sakamoto, Yen-Hsin Chou, Dr. Chang-Jen Jiang, Dr. Shin-Yu Miao, and Yoshinobu Odaira,
    (the&nbsp;<B><I>&ldquo;Current Director Nominees&rdquo;</I></B>&nbsp;) to serve on the Company&rsquo;s Board of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;)
    until the next annual shareholders meeting and until their successors are duly elected and qualified;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To elect Che Wei Hsu, Shuling
    Jiang and Kuang-Tseng Chen, (the&nbsp;<B><I>&ldquo;New Director Nominees,&rdquo; </I></B>together with the Current Director Nominees<B>,
    the &ldquo;<I>Director Nominees&rdquo;</I></B>) to serve on the Company&rsquo;s Board of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;)
    until the next annual shareholders meeting and until their successors are duly elected and qualified;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To ratify the selection
    of KCCW Accountancy Corp. (&ldquo;<B><I>KCCW</I></B>&rdquo;) as our independent auditor to audit the financial statements for the
    fiscal year ending on December 31, 2022;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve, by a non-binding
    vote, the Company&rsquo;s executive compensation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve, by a non-binding
    vote, the frequency of future Stockholder advisory votes relating to the Company&rsquo;s executive compensation; and,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To transact such other
    business as may properly come before the Meeting or any adjournment or postponement thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
BOARD UNANIMOUSLY RECOMMENDS A VOTE &ldquo;FOR&rdquo; ALL OF THE NOMINEES LISTED ABOVE AND &ldquo;FOR&rdquo; EACH OF THE OTHER PROPOSALS
EXCEPT &ldquo;THREE YEARS&rdquo; FOR PROPOSAL NO. 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of record of the Company&rsquo;s Common Stock at the close of business on April 20, 2022 (the&nbsp;<B><I>&ldquo;Record Date&rdquo;</I></B>)
will be entitled to notice of, and to vote at, this Meeting and any adjournment or postponement thereof. Each share of Common Stock entitles
the holder thereof to one vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
vote is important, regardless of the number of shares you own. Due to the virtual nature of the Meeting, you are urged to vote in favor
of each of the proposals by so indicating on the enclosed Proxy and by signing and returning the enclosed Proxy as promptly as possible,
before 11:59 p.m. EST on May 19, 2022, whether or not you plan to attend the Meeting virtually. <B>The enclosed Proxy is solicited by
the Company&rsquo;s Board of Directors. </B>Any shareholder giving a Proxy may revoke it prior to the time it is voted by notifying the
Secretary, in writing, to that effect, by filing with him/her a later dated Proxy. You will not be able to vote at the Meeting; therefore,
it is strongly recommended that you complete the enclosed proxy card before 11:59 p.m. EST on May 19, 2022, to ensure that your shares
will be represented at this Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
complete list of Shareholders of record entitled to vote at this Meeting will be available for ten days before this Meeting at the principal
executive office of the Company for inspection by Shareholders during ordinary business hours for any purpose germane to this Meeting.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Whether
or not you plan to attend the annual meeting, we urge you to read this notice carefully and to vote your shares. Your vote is very important.
</B>If you are a registered shareholder, please vote your shares as soon as possible by completing, signing, dating and returning the
enclosed proxy card in the postage-paid envelope provided. If you hold your shares in &ldquo;street name&rdquo; through a bank, broker
or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your
shares are represented and voted at the annual meeting. If you sign, date and return your proxy card without indicating how you wish
to vote, your proxy will be voted FOR each of the proposals to be considered at the annual meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
want to thank all of our shareholders as we look forward to what we believe will be an exciting future for our business.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
strongly encourage you to vote by proxy as described in the Proxy Statement so that your vote can be counted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
notice and the enclosed proxy statement are first being mailed to Shareholders on or about April 27, 2022.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are urged to review carefully the information contained in the enclosed proxy statement prior to deciding how to vote your shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By Order of the Board,</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Howard
    Doong</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard Doong</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 20, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IF
YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED &ldquo;FOR&rdquo; ALL OF THE NOMINEES
LISTED ABOVE AND &ldquo;FOR&rdquo; EACH OF THE OTHER PROPOSALS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Important
Notice Regarding the Availability of Proxy Materials</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>for
the Annual Shareholder Meeting to Be Held at 9:00 p.m., local time in Taiwan (or 9:00 a.m. EST) on</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>May 20, 2022 Eastern Standard Time</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notice of Annual Meeting, proxy statement and Annual Report on Form 10-K for year ended December 31, 2021 are available at&nbsp;www.proxyvote.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 91%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUESTIONS AND ANSWERS
    ABOUT THESE PROXY MATERIALS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE ANNUAL MEETING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date, Time and Place of
    the Meeting</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purpose of the Meeting</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Record Date and Voting
    Power</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">5</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum and Required Vote</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revocability of Proxies</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Solicitation Costs</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Right of Appraisal</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Who Can Answer Your Questions
    About Voting Your Shares</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Offices</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSAL NO. 1&nbsp;&mdash;&nbsp;RE-ELECTION
    OF DIRECTORS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Qualifications and
    Director Nominees</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information Regarding the
    Company&rsquo;s Directors and Nominees</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Required</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSAL NO. 2&nbsp;&mdash;&nbsp;ELECTION
    OF DIRECTORS</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Qualifications and
    Director Nominees</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information Regarding the
    Company&rsquo;s Directors and Nominees</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Required</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommendation of the Board</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain
    Beneficial Owners and Management</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Certain Relationships and Related Party Transactions</P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">16</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSAL
    NO. 3&nbsp;&mdash;&nbsp;RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees
    and Services</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">20</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Policies and Procedures
    Relating to Approval of Services by our Independent Registered Public Accountants</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">20</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Required</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommendation of the Board</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSAL
    NO. 4 &mdash; ADVISORY VOTE ON EXECUTIVE COMPENSATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purpose</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Required</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommendation of the Board</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">21</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSAL
    NO. 5 - ADVISORY VOTE ON FREQUENCY OF ADVISORY VOTES ON EXECUTIVE COMPENSATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purpose</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">21</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote Required</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommendation of the Board</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER INFORMATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deadline for Submission
    of Shareholder Proposals for 2023 Annual Meeting of Shareholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Solicitation</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of Proxy Materials
    to Households</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find Additional
    Information</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABVC
BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROXY
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022
ANNUAL MEETING OF SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>to
be held on May 20, 2022, at 9:00 p.m., local time in Taiwan, 9:00 a.m. Eastern Standard Time</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUESTIONS
AND ANSWERS ABOUT THESE PROXY MATERIALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Why
am I receiving this proxy statement?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
notice provides some details about the proposals on which our Board would like you, as a stockholder, to vote at the Meeting, which will
take place at 9:00 p.m., local time in Taiwan (or 9:00 a.m. EST) , on Friday, May 20, 2022 via the Zoom link below. Due to the continued
public health impact of the coronavirus, or COVID-19, the Company has decided to hold the Annual Meeting of Shareholders as a virtual
electronic meeting using Zoom video webinar. To assist in protecting the well-being and health of our shareholders and employees, the
Meeting will be held virtually via the Internet only <U>with no physical in-person meeting</U> except the Board of Directors. In addition
to on-line attendance, shareholders can hear all portions of the Meeting, submit written questions during the Meeting and listen to live
responses to shareholder questions. <B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
attend the virtual Meeting via Zoom, go to the link below: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://us06web.zoom.us/webinar/register/WN_N4Og75-7SC-D69RZENZRMg</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
you register with your name and email address, so that we can log attendees, you will be taken into the waiting room until the meeting
begins.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recommend you log in at least 15 minutes before the Meeting to ensure you are logged in when the meeting starts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
are being asked to consider and vote upon proposals to (i) re-elect the Current Director Nominees to the Board to serve one-year terms,
(ii) elect the New Director Nominees to the Board to serve one-year term, (iii) ratify the selection of KCCW as our independent registered
public accounting firm for 2022, (iv) approve, by a non-binding vote, the Company&rsquo;s executive compensation; (v) approve, by a non-binding,
vote the frequency of future Stockholder advisory votes relating to the Company&rsquo;s executive compensation; and (vi) transact such
other business as may properly come before the Meeting or any adjournment or postponement thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement also gives you information on the proposals so that you can make an informed decision. You should read it carefully.&nbsp;Your
vote is important.<B>&nbsp;</B>You are encouraged to submit your proxy card as soon as possible after carefully reviewing this proxy
statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this proxy statement, we refer to ABVC BioPharma, Inc. as the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Who
can vote at this Meeting?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
who owned shares of our common stock, $0.001 par value per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;) on April 20, 2022
(the &ldquo;<B><I>Record Date</I></B>&rdquo;) may attend and vote at this Meeting. There were 30,307,329 shares of Common Stock
outstanding on the Record Date. All shares of Common Stock shall have one vote per share. Information about the stockholdings of our
directors, executive officers and significant Shareholders is contained in the section of this proxy statement entitled
&ldquo;Security Ownership of Certain Beneficial Owners and Management&rdquo; beginning on page 19 of this proxy
statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is the proxy card?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
card enables you to appoint Howard Doong as your representative at this Meeting. By completing and returning the proxy card, you are
authorizing these persons to vote your shares at this Meeting in accordance with your instructions on the proxy card. This way, your
shares will be voted whether or not you attend this Meeting. Even if you plan to attend this Meeting, it is strongly recommended to complete
and return your proxy card before 11:59 p.m. EST on May 19, 2022 in case your plans change. If a proposal comes up for vote at this Meeting
that is not on the proxy card, the proxies will vote your shares, under your proxy, according to their best judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
does the Board recommend that I vote?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board unanimously recommends that stockholders vote &ldquo;FOR&rdquo; each of the Director Nominees listed in proposal No. 1 and 2 and
&ldquo;FOR&rdquo; each of proposals No. 3 and 4 and &ldquo;THREE YEARS&rdquo; for proposal No. 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is the difference between holding shares as a shareholder of record and as a beneficial owner?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our Shareholders hold their shares in an account at a brokerage firm, bank or other nominee holder, rather than holding share certificates
in their own name. As summarized below, there are some distinctions between shares held of record and those owned beneficially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
of Record/Registered Shareholders</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
on the Record Date, your shares were registered directly in your name with our transfer agent, Vstock Transfer, you are a &ldquo;Shareholder
of record&rdquo; and we are sending these proxy materials directly to you. As the Shareholder of record, you have the right to direct
the voting of your shares by returning the enclosed proxy card to us. Whether or not you plan to attend the Meeting, please complete,
date and sign the enclosed proxy card to ensure that your vote is counted.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Beneficial
Owner</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
on the Record Date, your shares were held in an account at a brokerage firm or at a bank or other nominee holder, you are considered
the beneficial owner of shares held &ldquo;in street name,&rdquo; and these proxy materials are being forwarded to you by your broker
or nominee who is considered the Shareholder of record for purposes of voting at the Meeting. As the beneficial owner, you have the right
to direct your broker on how to vote your shares and to attend the Meeting. However, since you are not the Shareholder of record, you
may not vote these shares in person unless you receive a valid proxy from your brokerage firm, bank or other nominee holder. To obtain
a valid proxy, you must make a special request of your brokerage firm, bank or other nominee holder. If you do not make this request,
you can still vote by using the voting instruction card enclosed with this proxy statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
do I vote?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you were a stockholder of record of the common stock on the Record Date, you may vote in any of the methods described below. Each share
of common stock entitles the holder thereof to one vote on the applicable proposals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may vote in one of three ways:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over the Internet</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
your shares are registered in your name:</I>&nbsp;Vote your shares over the Internet by accessing the proxy online voting website at:&nbsp;<I>www.proxyvote.com</I>&nbsp;and
following the on-screen instructions. You will need the control numbers that appear on your proxy card when you access the web page.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
your shares are held in the name of a broker, bank or other nominee:</I>&nbsp;Vote your shares over the Internet by following the voting
instructions that you receive from such broker, bank or other nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By Telephone</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
your shares are registered in your name:</I>&nbsp;Vote your shares over the telephone by accessing the telephone voting system toll-free
at 1-800-690-6903 in the United States and from foreign countries using any touch-tone telephone and following the telephone voting instructions.
The telephone instructions will lead you through the voting process. You will need the Company number, account and control numbers that
appear on your proxy card.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By Mail</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vote
by signing and dating the proxy card(s) and returning the card(s) in the prepaid envelope.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we receive your proxy card prior to this Meeting and if you mark your voting instructions on the proxy card, your shares will be voted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
you instruct; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">according
to the best judgment of the appointed Proxy if a proposal comes up for a vote at this Meeting that is not on the proxy card.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you return a signed card, but do <U>not</U> provide voting instructions, your shares will be voted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR each nominee for director;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR the selection of KCCW
    as our independent registered public accounting firm for year ending December 31, 2022;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR the approval, by a
    non-binding vote, the Company&rsquo;s executive compensation;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR the recommendation
    of every THREE (3) years as the desired frequency for the Company to hold a non-binding, advisory vote of the stockholders on executive
    compensation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the best judgment
    of Mr. Doong if a proposal comes&nbsp;up for a vote at the Meeting that is not on the proxy card.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
I plan on attending the Meeting, should I return my proxy card?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
Whether or not you plan to attend the Meeting, after carefully reading and considering the information contained in this proxy statement,
please complete and sign your proxy card. Then return the proxy card in the pre-addressed, postage-paid envelope provided herewith as
soon as possible, but prior to 11:59 p.m. EST on May 19, 2022, so your shares may be represented at the Meeting. <B><I>There will not
be any voting at the Meeting. </I></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>May
I change my mind after I return my proxy?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
You may revoke your proxy and change your vote at any time before the polls close at this Meeting. You may do this by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sending a written notice
    to the Secretary of the Company at the Company&rsquo;s executive offices stating that you would like to revoke your proxy of a particular
    date; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">signing another proxy card
    with a later date and returning it to the Secretary before the polls close at this Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
does it mean if I receive more than one proxy card?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may have multiple accounts at the transfer agent and/or with brokerage firms. Please sign and return all proxy cards to ensure that all
of your shares are voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
happens if I do not indicate how to vote my proxy?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed
and dated proxies received by the Company without an indication of how the Shareholder desires to vote on a proposal will be voted in
favor of each director and proposal presented to the Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Will
my shares be voted if I do not sign and return my proxy card?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you do not sign and return your proxy card, your shares will not be voted.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
many votes are required to elect the Director Nominees as directors of the Company?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
election of directors is based on a plurality of the votes represented at the Meeting or by proxy and entitled to vote in the election
of directors at the Meeting. Abstentions and broker non-votes will have no effect on the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
many votes are required to ratify KCCW as the Company&rsquo;s independent registered public accounting firm for year ending December
31, 2022?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposal to ratify the appointment of KCCW to serve as our independent registered public accounting firm for 2022 requires the affirmative
vote of a majority of the votes cast at the Meeting by the holders of shares of Common Stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
many votes are required to approve, by a non-binding vote, the Company&rsquo;s executive compensation?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposal to approve, by a non-binding vote, the Company&rsquo;s executive compensation requires the affirmative vote of a majority of
the votes cast at the Meeting by the holders of shares of Common Stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
many votes are required to approve, by a non-binding vote, the frequency of future Stockholder advisory votes relating to the Company&rsquo;s
executive compensation?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposal to approve, by a non-binding, vote the frequency of future Stockholder advisory votes relating to the Company&rsquo;s executive
compensation requires the affirmative vote of a majority of the votes cast at the Meeting by the holders of shares of Common Stock entitled
to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Is
my vote kept confidential?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxies,
ballots and voting tabulations identifying Shareholders are kept confidential and will not be disclosed, except as may be necessary to
meet legal requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Where
do I find the voting results of this Meeting?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will announce voting results at this Meeting and also file a Current Report on Form 8-K with the Securities and Exchange Commission (the
&ldquo;<B>SEC</B>&rdquo;) reporting the voting results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Who
can help answer my questions?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can contact Yvonne Chen at info@ambrivis.com or by sending a letter to the offices of the Company at 44370 Old Warm Springs Blvd., Fremont,
CA 94538 with any questions about proposals described in this proxy statement or how to execute your vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
CAN I GET A COPY OF THE PROXY MATERIALS?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of our 2021 Annual Report, including consolidated financial statements as of and for the year ended December 31, 2021, the proxy card,
the Notice and this Proxy Statement are available on our Company&rsquo;s website at http://www.abvcpharma.com. The contents of that website
are not a part of this Proxy Statement. If you want to receive a paper or email copy of the Company&rsquo;s 2021 Annual Report, you must
request one. There is no charge to you for requesting a copy. Please make your request for a copy by contacting Yvonne Chen at: info@ambrivis.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
ANNUAL MEETING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are furnishing this proxy statement to you, as a shareholder of ABVC BioPharma, Inc., as part of the solicitation of proxies by our Board
for use at the Meeting to be held on May 20, 2022, and any adjournment or postponement thereof. This proxy statement is first being furnished
to Shareholders on or about April 27, 2022. This proxy statement provides you with information you need to know to be able to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date,
Time and Place of the Meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Meeting will be held virtually on May 20, 2022, at 9:00 p.m., local time in Taiwan/9:00 a.m. EST, or such other date, time and place
to which the Meeting may be adjourned or postponed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose
of the Meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Meeting, the Company will ask Shareholders to consider and vote upon the following proposals:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To re-elect the Current
    Director Nominees to serve on the Company&rsquo;s Board of Directors until the next annual shareholders meeting and until their successors
    are duly elected and qualified;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To elect the New Director
    Nominees to serve on the Company&rsquo;s Board of Directors until the next annual shareholders meeting and until their successors
    are duly elected and qualified;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To ratify the selection
    of KCCW as our independent registered public accounting firm for year ending December 31, 2022;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To conduct a non-binding
    vote on the Company&rsquo;s executive compensation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To conduct a non-binding
    vote on the frequency of future Stockholder advisory votes relating to the Company&rsquo;s executive compensation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To transact such other
    business as may properly come before the Meeting or any adjournment or postponement thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Record
Date and Voting Power</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board fixed the close of business on April 20, 2022, as the record date for the determination of the outstanding shares of Common Stock
entitled to notice of, and to vote on, the matters presented at this Meeting. As of the Record Date, there were 30,307,329 shares of
Common Stock outstanding. Each share of Common Stock entitles the holder thereof to one vote. Accordingly, a total 30,307,329 votes may
be cast at this Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quorum
and Required Vote</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 12.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
quorum of Shareholders is necessary to hold a valid meeting. The presence in person or by proxy of the holders of a majority of the shares
entitled to vote thereat constitutes a quorum. Abstentions and broker non-votes&nbsp;<I>(i.e.&nbsp;</I>shares held by brokers on behalf
of their customers, which may not be voted on certain matters because the brokers have not received specific voting instructions from
their customers with respect to such matters) will be counted solely for the purpose of determining whether a quorum is present at the
Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
No. 1 shall be decided by a plurality of the shares of common stock represented at the Meeting or by proxy and entitled to vote in the
election of directors at the Meeting. Abstentions and broker non-votes will have no effect on the election of directors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
No. 2 shall be decided by a plurality of the shares of common stock represented at the Meeting or by proxy and entitled to vote in the
election of directors at the Meeting. Abstentions and broker non-votes will have no effect on the election of directors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
No. 3 requires the affirmative vote of the majority of the shares present in person or represented by proxy at the Meeting and entitled
to vote thereon. Abstentions and broker non-votes will have no direct effect on the outcome of this proposal;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
No. 4 requires the affirmative vote of the majority of the shares present in person or represented by proxy at the Meeting and entitled
to vote thereon. Abstentions and broker non-votes will have no direct effect on the outcome of this proposal; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
No. 5 requires the affirmative vote of the majority of the shares present in person or represented by proxy at the Meeting and entitled
to vote thereon. Abstentions and broker non-votes will have no direct effect on the outcome of this proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revocability
of Proxies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
proxy may be revoked by the shareholder of record giving it at any time before it is voted. A proxy may be revoked by (A) sending to
our Secretary, at ABVC BioPharma, Inc., 44370 Old Warm Springs Blvd., Fremont, CA 94538, USA, either (i) a written notice of revocation
bearing a date later than the date of such proxy or (ii) a subsequent proxy relating to the same shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the shares are held by the broker or bank as a nominee or agent, the beneficial owners should follow the instructions provided by their
broker or bank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proxy
Solicitation Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of preparing, assembling, printing and mailing this proxy statement and the accompanying form of proxy, and the cost of soliciting
proxies relating to this Meeting, will be borne by the Company. If any additional solicitation of the holders of our outstanding shares
of Common Stock is deemed necessary, we (through our directors and officers) anticipate making such solicitation directly. The solicitation
of proxies by mail may be supplemented by telephone, telegram and personal solicitation by officers, directors and other employees of
the Company, but no additional compensation will be paid to such individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Right of Appraisal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nevada law, the Company&rsquo;s stockholders are not entitled to&nbsp;appraisal&nbsp;rights in connection with any of the proposals to be acted
upon at the Meeting.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Who
Can Answer Your Questions about Voting Your Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can contact Yvonne Chen at info@ambrivis.com or by sending a letter to the offices of the Company at 44370 Old Warm Springs Blvd., Fremont,
CA 94538, USA, with any questions about proposals described in this proxy statement or how to execute your vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
Offices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal executive offices of our Company are located at 44370 Old Warm Springs Blvd., Fremont, CA 94538. The Company&rsquo;s telephone
number at such address is 510-668-0881.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSAL
NO. 1 &mdash; RE-ELECTION OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominees listed below have been nominated by the Corporate Governance and Nominating Committee and approved by our Board to stand for
re-election as directors of the Company. Unless such authority is withheld, proxies will be voted for the election of the persons named
below, each of whom has been designated as a nominee. If, for any reason, any nominee/director becomes unavailable for election, the
proxies will be voted for such substitute nominee(s) as the Board may propose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
of our former directors, Dr. Hwalin Lee, Dr. Ming-Fong Wu and Shih-Chen Tzeng decided not to stand for re-election this year to pursue
other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Qualifications and Director Nominees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the collective skills, experiences and qualifications of our directors provide our Board with the expertise and experience
necessary to advance the interests of our Shareholders. While the Corporate Governance and Nominating Committee of our Board does not
have any specific, minimum qualifications that must be met by each of our directors, the Corporate Governance and Nominating Committee
uses a variety of criteria to evaluate the qualifications and skills necessary for each member of the Board. In addition to the individual
attributes of each of our current directors described below, we believe that our directors should have the highest professional and personal
ethics and values, consistent with our longstanding values and standards. They should have broad experience at the policy-making level
in business, exhibit commitment to enhancing Shareholder value and have sufficient time to carry out their duties and to provide insight
and practical wisdom based on their past experience.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Director Nominees recommended by the Board are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tsang Ming Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norimi Sakamoto</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director(2)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yen-Hsin Chou</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director (1)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tsung-Shann (T.S.) Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Strategy Officer (&ldquo;CSTRO&rdquo;) and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chang-Jen Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Shin-Yu Miao</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director(1)(2)(3)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoshinobu Odaira</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director(3)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of Audit Committee</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of Compensation Committee</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of Corporate Governance and Nominating Committee</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Regarding the Company&rsquo;s Directors and the Nominees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eugene
Jiang </B>has served as our CEO and President since the Company&rsquo;s inception in July 2015 until he resigned on September 15, 2017.
He remains the Chairman of the Board. From June 2015 until present, Mr. Jiang also serves as Director for&nbsp;BioLite&nbsp;Incorporation.
He also serves as&nbsp;CEO for&nbsp;Genepro&nbsp;Investment Company since March 2010.&nbsp;Mr.&nbsp;Jiang obtained an EMBA degree from
the University of&nbsp;Texas&nbsp;in Arrington in 2009. And in 2008, Mr. Jiang received a bachelor&rsquo;s degree in Physical Education
from Fu-Jen Catholic University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
T.S. Jiang</B>, has been the chairman of BioLite, Inc., a subsidiary of BioLite, Inc., since January 2010. Prior to BioLite, Dr. Jiang
served as the president and/or chairman of multiple biotech companies in Taiwan, including PhytoHealth Corporation from 1998 to 2009
and AmCad BioMed Corporation from 2008 to 2009. In addition, Dr. Jiang is a director on various biotech associations, such as the Taiwan
Bio Industry Organization (Taiwan) from 2006 to 2008 and the Chinese Herbs and Biotech Development Association in Taiwan from 2003 to
2006. Dr. Jiang was an assistant professor at University of Illinois from 1981 to 1987 and an associate professor at Rutgers, the State
University of New Jersey from 1987 to 1990 and served as a professor at a few Taiwanese universities during a period from 1990 to 1993,
such as National Taiwan University, National Cheng Kung University and Tunghai University. Dr. Jiang obtained his bachelor degree in
Engineering and Chemical Engineering from National Taiwan University in Taiwan in 1976, masters and Ph.D. from Northwestern University
in the U.S. in 1981 and Executive Master of Business Administration (&ldquo;EMBA&rdquo;) from National Taiwan University in Taiwan in
2007. As a successful entrepreneur, Dr. Jiang has developed and commercialized PG2 Lyo Injection, a new drug to treat cancer related
fatigue. From 1998 to 2009, Dr. T. S. Jiang served as President of Phyto Health Corporation where he led a project team to develop PG2
Injectable. This product was extracted, isolated and purified from a type of Traditional Chinese Medicine. PG2 Injection was intended
for cancer patients who had trouble recovering from severe fatigue. Dr. Jiang oversaw and managed the R&amp;D department, daily corporate
operations and business of Phyto Health Corporation when he was the President. PG2 Lyo Injection received approval on its NDA from Taiwan
Food and Drug Administration in 2010 and later was launched into the Taiwan market in 2012. We believe that Dr. Jiang provides leadership
and technological guidance on our strategic development and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Tsang Ming Jiang</B>, has served as a technical director at the Industrial Technology Research Institute in Taiwan since January 2017.
Prior to joining the Industrial Technology Research Institute as a technical director, Dr. Jiang worked at the Company as chief information
officer from November 2016 to January 2017, Ericsson as engineering manager from 2013 to 2016 and the Industrial Technology Research
Institute as deputy director from October 2011 to February 2013. In addition, Dr. Jiang worked at several other research institutes,
including University of Alaska Fairbanks, National Taiwan University and Chung Cheng University, with his research interest in cloud
computing and Internet security, especially in the areas of virtualization, software-defined data centers, SDN enabled networks and big
data analytics. Dr. Jiang received his Bachelor of Science in electrical engineering in 1982 and Master of Science in electrical engineering
in 1984, both from National Taiwan University, and his Ph.D. in electrical engineering and computer science from University of Illinois
at Chicago in 1988. Dr. Tsang Ming Jiang is a brother of Dr. Tsung-Shann Jiang, who together with his wife collectively owns 80% of Lion
Arts Promotion, Inc. which has approximately 69.3% of ownership interest in the Company through YuanGene Corporation, a wholly-owned
subsidiary of Lion Arts Promotion, Inc.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Norimi
Sakamoto</B>, currently serves at four enterprises, Shogun Maitake Canada Co., Ltd. as an executive officer and business development
manager from 2015, Shogun Maitake Odaira Enterprise Ltd as an executive officer from 2017, Odaira Corporation Co., Ltd. as chief executive
officer since 2014 and MyLife Corporation as president and chief executive officer since 2012. Ms. Sakamoto started her career in 1997
from Sumitomo Corporation Hokkaido Co., Ltd. in Japan. Ms. Sakamoto received her Bachelor Degree of Arts in travel and tourism from Davis
and Elkins College in 1993 and Master of Science in urban studies from the University of New Orleans in 1995.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yen-Hsin
Chou</B>, has served as a clerk at Mega Securities Co., Ltd. since 2011. Ms. Chou&rsquo;s responsibilities primarily include selling
various types of securities, including futures, funds and insurance, managing clients&rsquo; accounts and business development. Ms. Chou
received a Bachelor Degree from Yuan Chi University School of Economics in 2011.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Chang-Jen Jiang</B>, has been an attending doctor at the department of pediatrics of Eugene Women and Children Clinic since 2009. Previously,
Dr. Chang-Jen worked as an attending doctor at the department of pediatrics of Keelung Hospital, the Ministry of Health and Welfare in
Taiwan from 1994 to 2009. Before his position at Keelung Hospital, he was a chief doctor at the department of pediatrics, hematology
and oncology of Mackay Memorial Hospital in Taiwan for three years until 1994. Dr. Chang-Jen Jiang obtained his doctor of medicine degree
(the Taiwanese equivalent degree of MD) from Taipei Medical University in Taiwan in 1982 and started his career in Mackay Memorial Hospital.
We believe that the Company will benefit from Dr. Jiang&rsquo;s knowledge in biology and experiences in medical practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Shin-Yu Miao</B>, has served as an associate professor at Ling Tung University Department of Applied Foreign Languages since 2004. She
served as a lecturer from 1996 to 2004. Ms. Miao received her M.S. in Adult Education from the University of Manchester in 1995 and Ph.D.
in Adult Education from the University of South Australia in 2004. We believe that Ms. Miao&rsquo;s familiarity with biotech research
centers will be a valuable resource for our drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yoshinobu
Odaira</B>, is an entrepreneur and has founded a number of Japanese agricultural companies, including Yukiguni Maitake, our licensing
partner. In 1983, Mr. Odaira established Yukiguni Maitake, which became a public company in Japan in 1994. In 2015, Bain Capital Private
Equity purchased Yukiguni Maitake through a tender offer. In addition to his success with Yukiguni Maitake, Mr. Odaira served as the
CEO of Yukiguni Shoji Co., Ltd. since 1988 and the CEO of Odaira Shoji Co., Ltd. from 1989.&nbsp; In 2015, Mr. Odaira founded two new
companies, Shogun Maitake Canada Co., Ltd. in Canada and Odaira Kinoko Research Co., Ltd. in Japan. Yoshinobu Odaira graduated from the
Ikazawa Junior High School in 1963. We believe that we will benefit from Mr. Odaira&rsquo;s successful business experience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vote
Required</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
director nominees shall be elected by a plurality of the total votes properly cast electronically or by proxy at the Meeting by the holders
of common stock vote &ldquo;FOR&rdquo; the proposal. Abstentions and broker non-votes will have no effect on the result of the vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recommendation
of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Board unanimously recommends that you vote all of your shares &ldquo;FOR&rdquo; the election to the Board of all of the nominees described
in this Proposal&nbsp;No. 1.</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSAL
NO. 2&nbsp;&mdash;&nbsp;ELECTION OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominees listed below have been nominated by the Corporate Governance and Nominating Committee and approved by our Board to stand for
election as directors of the Company. Unless such authority is withheld, proxies will be voted for the election of the persons named
below, each of whom has been designated as a nominee. If, for any reason, any nominee/director becomes unavailable for election, the
proxies will be voted for such substitute nominee(s) as the Board may propose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Qualifications and Director Nominees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the collective skills, experiences and qualifications of our directors provide our Board with the expertise and experience
necessary to advance the interests of our Shareholders. While the Corporate Governance and Nominating Committee of our Board does not
have any specific, minimum qualifications that must be met by each of our directors, the Corporate Governance and Nominating Committee
uses a variety of criteria to evaluate the qualifications and skills necessary for each member of the Board. In addition to the individual
attributes of each of our current directors described below, we believe that our directors should have the highest professional and personal
ethics and values, consistent with our longstanding values and standards. They should have broad experience at the policy-making level
in business, exhibit commitment to enhancing Shareholder value and have sufficient time to carry out their duties and to provide insight
and practical wisdom based on their past experience.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Director Nominees recommended by the Board are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Che
    Wei Hsu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuling
    Jiang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuang-Tseng
    Chen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
member of Audit Committee</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
member of Compensation Committee</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
member of Corporate Governance and Nominating Committee</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Regarding the Company&rsquo;s Directors and the Nominees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Che
Wei Hsu</B> is currently employed by Chunghwa Post Co., Ltd.; previously she was a teacher in a Junior High School. Ms. Hsu received
a Bachelor Degree from Tunghai University School of Chinese Literature in 2004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shuling
Jiang</B> has served as a director for various companies, including BioLite, Inc., BioFirst Corp, Lion Arts Promotion, Inc., since 2017
and started to serve as Managing Director for Biokey, Inc. in March 2022. Ms. Jiang received a Bachelor Degree from National Taiwan Normal
University School of Music in 1978 and a Master Degree from Northwestern University School of Music in 1983.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kuang-Tseng
Chen </B>founded the real estate company Hao Ting Co., Ltd. in 2008. Mr. Chen received a Bachelor Degree from National Taiwan University
School of Chemical Engineering in 1976.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vote
Required</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
director nominees shall be elected by a plurality of the total votes properly cast electronically or by proxy at the Meeting by the holders
of common stock vote &ldquo;FOR&rdquo; the proposal. Abstentions and broker non-votes will have no effect on the result of the vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recommendation
of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Board unanimously recommends that you vote all of your shares &ldquo;FOR&rdquo; the election to the Board of all of the nominees described
in this Proposal&nbsp;No. 2.</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth as of the date of this report, the name, age, and position of each executive officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is certain biographical information regarding each of our officers, that is not also a director, as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chihliang An</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (&ldquo;CFO&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tsung-Shann (T.S.) Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Strategy Officer (&ldquo;CSTRO&rdquo;) and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Howard Doong</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (&ldquo;CEO&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chi-Hsin (Richard) King</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer (&ldquo;CSO&rdquo;)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Howard Doong</B>, was appointed as the Company&rsquo;s new CEO on September 15, 2017. In addition to the position at the Company, Dr.
Doong also serves as the Chairman and the CEO of&nbsp; LifeCode Biotechnology Company (&ldquo;LifeCode&rdquo;), a Taiwan company in the
biotechnology business, since 2017. At the same time, he also serves as the CSO of Wuhan Frasergen Genomic Medicine Company (&ldquo;Wuhan
Frasergen Genomic&rdquo;), a Chinese company in the biotechnology business, since 2016. He served as the CSO of Cold Spring Biotech Corporation,
a Taiwan corporation in the biotechnology business from 2014 to 2016. He served as the CEO of iKnowledge-Care Bioscience Corp, a Taiwan
company in the biotechnology business from 2014 to 2015. He served as the director of Taipei Veteran General Hospital-LihPao Laboratory
of Cancer Genomic Medicine from 2012 to 2013. He served as the Vice President and director of Quality Assurance, TrimGen Corporation,
a Maryland corporation in the biotechnology business from 2006 to 2011. Before 2006, Dr. Doong was a professor at the University of Maryland
School of Medicine and Biotechnology Institute, and a researcher at National Cancer Institute (NCI) of the National Institutes of Health
(NIH). Dr. Doong received his Ph.D. degree from University of Chicago, the Department of Organismal Biology and Anatomy and the Department
of Surgery. He received his M.D and Ph.D. degree from Harvard-MIT Division of Health Sciences and Technology. He received his M.S. degree
from the University of New Hampshire, Genetics Program and B.S. degree from Fu-Jen Catholic University, Taiwan, Department of Biology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mr.
Chihliang An</B>, was the Managing Director of Investment Team at Yintai Investment (Hong Kong) since September 2018 to June 2019. Prior
to that, Mr. An served as a Senior Director of Sales and Operations at Goertek (USA) from March 2017 to August 2018 and a Director of
Finance at BioKey, Inc., which is a wholly-owned subsidiary of the Company now, from March 2015 to February 2017. Mr. Chihliang An received
a Bachelor of Art degree in Statistics from Tamkang University in Taiwan in 2003 and an MBA in Finance from University of Kentucky in
2007.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Chi-Hsin Richard King&mdash;Chief Scientific Officer, </B>effective September 15, 2017, the Board appointed Dr. Chi-Hsin Richard King
as the CSO of the Company. Dr. Chi-Hsin Richard King, 71, retired since July 2017. He served as the consultant at TaiGen Biotechnology
Co. Ltd (&ldquo;TaiGen&rdquo;), a Taiwan company in the biotechnology business, from August 2016 to July 2017, the Senior Vice President
at TaiGen from July 2008 to August 2016 and as the Vice President at Research and Development of TaiGen from June 2005 to July 2008.
Dr. King served as the Director at Albany Molecular Research Inc. (&ldquo;AMRI&rdquo;), a New York corporation, from January 2003 to
June 2005, the Assistant Director at Medicinal Chemistry Department of AMRI from January 2000 to December 2002 and the Assistant Director
at Chemical Development Department of AMRI from August 1997 to January 2000. Dr. King received the Ph. D. degree of organic chemistry
from University of Utah in March 1980, and B.S. degree of chemistry from National Taiwan Normal University in July 1972.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Director
Independence</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NASDAQ Rules require that a majority of the Board be independent. The Board currently consists of 11 directors, of which nine are non-management
directors. Each year the Board reviews the materiality of any relationship that each of our directors has with the Company, either directly
or indirectly. For information about related party transactions, see &ldquo;Related Party Transactions&rdquo; further down in this statement.
Based on this review, the Board has determined that the following current directors and New Director Nominees are &ldquo;independent
directors&rdquo; as defined by the NASDAQ Rules: Messrs. Miao, Odaira, and Chen and Mses. Sakamoto, Chou and Hsu.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
director who is a member of the Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee
is an independent director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Meetings
of the Board of Directors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal year ended December 31, 2021, the Company&rsquo;s Board of Directors held 9 meetings of the board and approved several other actions
via unanimous written consent. All directors are expected to attend meetings and their attendance is recorded in the minutes. All members
attended all meetings.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Committees
of the Board of Directors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
established an audit committee, a compensation committee and a corporate governance and nominating Committee. Each of the committees
of the Board have the composition and responsibilities described below, assuming all Director Nominees are elected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Audit
Committee</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board of Directors consists of Ms. Chou, Yen-Hsin (Chair), Mr. Wu, Chen, Ming-Fong and Ms. Miao and Shin-Yu. The
functions of the Audit Committee include the retention of our independent registered public accounting firm, reviewing and approving
the planned scope, proposed fee arrangements and results of the Company&rsquo;s annual audit, reviewing the adequacy of the Company&rsquo;s
accounting and financial controls and reviewing the independence of the Company&rsquo;s independent registered public accounting firm.
The Board has determined that Ms. Chou and Ms. Maio are each an &ldquo;independent director&rdquo; under the listing standards of The
NASDAQ Stock Market. The Board of Directors has also determined Ms. Chou is an &ldquo;audit committee financial expert&rdquo; within
the applicable definition of the SEC. The Audit Committee is governed by a written charter approved by the Board of Directors, a copy
of which is available on our website at www.abvcpharma.com. Information contained on our website are not incorporated by reference into
and do not form any part of this reports. We have included the website address as a factual reference and do not intend it to be an active
link to the website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is determined that Ms. Yen-Hsin Chou, possesses accounting or related financial management experience that qualifies him as an &ldquo;audit
committee financial expert&rdquo; as defined by the rules and regulations of the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee of the Board of Directors currently consists of Mr. Hsu, Ms. Miao and Ms. Sakamoto. The functions of the Compensation
Committee include the approval of the compensation offered to our executive officers and recommending to the full Board of Directors
the compensation to be offered to our directors, including our Chairman. The Board has determined that Ms. Sakamoto (Chair) and Ms. Maio
are each an &ldquo;independent director&rdquo; under the listing standards of The NASDAQ Stock Market LLC. In addition, the members of
the Compensation Committee qualify as &ldquo;non-employee directors&rdquo; for purposes of Rule 16b-3 under the Exchange Act and as &ldquo;outside
directors&rdquo; for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended. The Compensation Committee is governed
by a written charter approved by the Board of Directors, a copy of which is available on our website at www.abvcpharma.com. Information
contained on our website are not incorporated by reference into and do not form any part of this report. We have included the website
address as a factual reference and do not intend it to be an active link to the website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Corporate
Governance and Nominating Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporate Governance and Nominating Committee of the Board of Directors consists of Mr. Yoshinobu Odaira (Chair), Mr. Hsu and Ms.&nbsp;Miao,
each of whom is an independent director under Nasdaq&rsquo;s listing standards. The corporate governance and nominating committee is
responsible for overseeing the selection of persons to be nominated to serve on our board of directors. The corporate governance and
nominating committee considers persons identified by its members, management, shareholders, investment bankers and others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guidelines
for Selecting Director Nominees</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidelines for selecting nominees, which are specified in the Corporate Governance and Nominating Committee Charter, generally provide
that persons to be nominated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">should have
    demonstrated notable or significant achievements in business, education or public service;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">should possess
    the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range
    of skills, diverse perspectives and backgrounds to its deliberations; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">should have
    the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate governance and nominating committee will consider a number of qualifications relating to management and leadership experience,
background and integrity and professionalism in evaluating a person&rsquo;s candidacy for membership on the board of directors. The nominating
committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise
from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board
members. The board of directors will also consider director candidates recommended for nomination by our shareholders during such times
as they are seeking proposed nominees to stand for election at the next annual meeting of shareholders (or, if applicable, a special
meeting of shareholders). Our shareholders that wish to nominate a director for election to the Board should follow the procedures set
forth in our bylaws. The nominating committee does not distinguish among nominees recommended by shareholders and other persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Family
Relationships</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
only family relationships among the executive officers and directors of the Company are: Dr. Tsang Ming Jiang, Dr. Tsung-Shann Jiang
and Dr. Chang-Jen Jiang who are brothers, Mr. Eugene Jiang who is Dr. Tsung-Shann Jiang&rsquo;s son and the marital relationship between
Yoshinobu Odaira and Norimi Sakamoto and between Shuling Jiang and Dr. Jiang. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Involvement
in Certain Legal Proceedings</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of our knowledge, none of our directors or executive officers has, during the past ten years, been involved in any legal proceedings
described in subparagraph (c)(2) of Item 103 of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
of Directors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors consists of 11 directors as of the date of April 20, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Terms
of Directors and Executive Officers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our directors holds office until a successor has been duly elected and qualified unless the director was appointed by the board of
directors, in which case such director holds office until the next following annual meeting of shareholders at which time such director
is eligible for reelection. All of our executive officers are appointed by and serve at the discretion of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Qualification</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no membership qualifications for directors. Further, there are no share ownership qualifications for directors unless so fixed by
us in a general meeting. There are no other arrangements or understandings pursuant to which our directors are selected or nominated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interested
Transactions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles of Incorporation, no contract or other transaction between the Company and one or more or its directors or officers,
or between the Company and any Company, firm or association in which one or more of its directors or officers are directors or officers
or are financially interested, is void or voidable solely for this reason or solely because any such director or officer is present at
the meeting of the board of directors or a committee thereof which authorizes or approves the contract or transaction, or because the
vote or votes of common or interested directors are counted for that purpose, if the circumstances specified in any of the following
paragraphs exist:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The fact of the common directorship, office or financial interest is disclosed or known to the board of directors or committee and noted
in the minutes, and the board or committee authorizes, approves or ratifies the contract or transaction in good faith by a vote sufficient
for the purpose without counting the vote or votes of the common or interested director or directors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The fact of the common directorship, office or financial interest is disclosed or known to the stockholders, and they approve or ratify
the contract or transaction in good faith by a majority vote of stockholders holding a majority of the voting power. The votes of the
common or interested directors or officers must be counted in any such vote of stockholders; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The contract or transaction is fair as to the Company at the time it is authorized or approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delinquent
Section 16(a) Reports</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires that the members of the Board, our executive officers and persons who own more than 10 percent of
a registered class of our equity securities file initial reports of ownership and reports of changes in ownership of our common units
and other equity securities with the SEC and any exchange or other system on which such securities are traded or quoted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
was the first year that our officers, directors and greater than 10% shareholders were subject to these rules. Based solely upon our
review of the Section 16(a) filings that have been furnished to us and representations by our directors and executive officers (where
applicable), we believe that all filings required to be made under Section 16(a) during the fiscal year ended December 31, 2021 were
timely made, except that during the fiscal year ended December 31, 2021, Mr. Chihliang An, failed to timely report his initial ownership
of our common stock on Form 3 and Dr. Ming-Fong Wu and Dr. Hwalin Lee failed to report each of his respective initial ownership of our
common stock on Form 3.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Executive Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The following tables set forth, for each of the
last two completed fiscal years of us, the total compensation awarded to, earned by or paid to any person who was a principal executive
officer during the preceding fiscal year and every other highest compensated executive officers earning more than $100,000 during the
last fiscal year (together, the &ldquo;Named Executive Officers&rdquo;). The tables set forth below reflect the compensation of the Named
Executive Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Summary Compensation</B>&nbsp;<B>Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Name&nbsp;and&nbsp;Principal&nbsp;Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<BR>
 ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<BR>
 ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<BR>
 Awards <BR>
($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR>
 Awards <BR>
($) (6)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity<BR>
 Incentive Plan <BR>
Compensation <BR>
($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change in <BR>
Pension <BR>
Value&nbsp;and <BR>
Nonqualified <BR>
Deferred <BR>
Compensation <BR>
Earnings<BR>
 ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other <BR>
Compensation ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <BR>
($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 26%">Howard Doong (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 7%">2021</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">200,000</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 5%">1,036,002</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">434,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chihliang An (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">687,668</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">356,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tsung-Shann Jiang (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">262,700</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,749</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306,749</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Richard Chi-Hsin King (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">861,834</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">434,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Eugene Jiang (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">262,700</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">207,585</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">407,585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Doong was appointed as the CEO on September 15, 2017.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. An was appointed as the CFO on September 1, 2019.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jiang was appointed as the CSTRO on September 1, 2019</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. King was appointed as the CSO on September 15, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang was appointed as CBO on September 1, 2019</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The weighted average grant date fair value of options granted during 2021 was $2.09, using the Black-Scholes option-pricing model. Accordingly, the Company recognized stock-based compensation expense of $2,675,205 for the years ended December 31, 2021.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Narrative Disclosure to Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Other than set out below, there are no arrangements
or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive
officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit
sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share
options may be granted at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our board approved and adopted the Amended and
Restated 2016 Equity Incentive Plan on September 12, 2020 (the &ldquo;Plan&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Grants of Plan-Based Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On November 21, 2020, the Company issued an aggregate
of 545,182 options to purchase shares of Common Stock in lieu of unpaid salaries of certain employees (other than Officers and Directors)
and unpaid consulting fees under the Plan, as amended; the total converted salaries was $1,090,361. The options are exercisable at $2.00
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On October 15, 2021, the Company&rsquo;s Board
of Directors approved and issued the following option awards pursuant to the Plan:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000
options to each director, including the Chairman; such options are exercisable at $3.00 per share.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
for 400,001 shares, 233,334 shares, and 316,667 shares to the CEO, CFO and CSO, respectively; the options are exercisable at $3.00 per
share.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As of the date of this report, we have granted
options under the Plan that can be exercised for an aggregate of 1,825,184 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards at Fiscal Year End</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The following table summarizes outstanding unexercised
options, unvested stocks and equity incentive plan awards held by each of our named executive officers, as of December 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OUTSTANDING EQUITY AWARDS AT FISCAL&nbsp;YEAR-END</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="19" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">OPTION AWARDS</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">STOCK AWARDS</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options (#)<BR> Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options (#)<BR> Unexercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Incentive<BR> Plan Awards:<BR> Number of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Unearned Options<BR> (#)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<BR> Exercise<BR> Prices<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<BR> Expiration<BR> Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares or<BR> Units of<BR> Stock That<BR> Have Not<BR> Vested<BR> (#)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Market<BR> Value of<BR> Shares or<BR> Units of<BR> Stock That<BR> Have Not<BR> Vested<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity<BR> Incentive Plan<BR> Awards:<BR> Number of<BR> Unearned<BR> Shares, Units<BR> or Other<BR> Rights That<BR> Have Not<BR> Been Issued<BR> (#)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Incentive<BR> Plan Awards:<BR> Market or Payout<BR> Value of Unearned<BR> Shares, Units or<BR> Other Rights That<BR> Have Not Been<BR> Issued<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-align: left">Howard Doong</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">85,715</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">10,715</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">2.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 6%; text-align: center">Nov 20, 2031</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Oct 15, 2032</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chihliang An</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,762</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Nov 20, 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">233,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Oct 15, 2032</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tsung-Shann&nbsp;Jiang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Nov 20, 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Oct 15, 2032</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Richard&nbsp;Chi-Hsin&nbsp;King</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Nov 20, 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Oct 15, 2032</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Eugene Jiang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,418</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Nov 20, 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">Oct 15, 2032</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Directors</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We paid all directors, including the Chairman,
30,000 stock options for each person in fiscal year 2021. We intend to pay all directors, including the Chairman, $3,500 monthly compensation
for each person during the term of their service, starting later this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>Pension, Retirement or Similar Benefit
Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">There are no arrangements or plans in which we
provide pension, retirement or similar benefits for directors or executive officers. We have no material bonus or profit sharing plans
pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may
be granted at the discretion of the board of directors or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment Contracts</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Dr. Howard Doong has entered into an employment
agreements (&ldquo;Doong Employment Agreement&rdquo;) with the Company, pursuant to which he shall receive an annual base salary of $100,000.
As of December 31, 2017, we paid Mr. Doong 20,833&nbsp;shares of the Company&rsquo;s common stock at a per share price of $1.60 as opposed
to cash compensation. Under Doong Employment Agreement, Dr. Doong is employed as our CEO and President of the Company. We may terminate
the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or
plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties.
In such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the
termination, and the executive officer&rsquo;s right to all other benefits will terminate, except as required by any applicable law. We
may also terminate an executive officer&rsquo;s employment without cause upon one-month advance written notice. In such case of termination
by us, we are required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The
executive officer may terminate the employment at any time with a one-month advance written notice if there is any significant change
in the executive officer&rsquo;s duties and responsibilities or a material reduction in the executive officer&rsquo;s annual salary. In
such case, the executive officer will be entitled to receive compensation equivalent to 12 months of the executive officer&rsquo;s base
salary. On August 21, 2019, all of the Board members present at the Meeting, unanimously reelected Dr. Howard Doong as the Chief Executive
Officer (&ldquo;CEO&rdquo;), which shall become effective on September 1, 2019 for a term of three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On August 21, 2019, all of the Board members present
at the Meeting unanimously appointed Mr. Chihliang An as the Company&rsquo;s Chief Financial Officer (&ldquo;CFO&rdquo;) effective from
September 1, 2019 for a term of three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Dr. Chi-Hsin Richard King has entered into an
employment agreements (&ldquo;King Employment Agreement&rdquo;) with the Company, pursuant to which he shall receive an annual base salary
of $50,000. As of December 31, 2017, we paid Mr. King 10,416 shares of the Company&rsquo;s common stock at a per share price of $1.60
as opposed to cash compensation. Under King Employment Agreement, Dr. King is employed as the CSO of the Company. We may terminate the
employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea
of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In
such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination,
and the executive officer&rsquo;s right to all other benefits will terminate, except as required by any applicable law. We may also terminate
an executive officer&rsquo;s employment without cause upon one-month advance written notice. In such case of termination by us, we are
required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The executive officer
may terminate the employment at any time with a one-month advance written notice if there is any significant change in the executive officer&rsquo;s
duties and responsibilities or a material reduction in the executive officer&rsquo;s annual salary. In such case, the executive officer
will be entitled to receive compensation equivalent to 12 months of the executive officer&rsquo;s base salary. On August 21, 2019, all
of the Board members present at the Meeting, unanimously reelected Dr. Richard King as the Chief Scientific Officer (&ldquo;CSO&rdquo;),
which shall become effective on September 1, 2019 for a term of three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On August 21, 2019, all of the Board members present
at the Meeting, except Eugene Jiang, appointed Mr. Eugene Jiang, the current Chairman of the Board, as the Chief Business Officer, effective
since September 1, 2019 for a term of three years. Mr. Eugene Jiang excused himself from the discussion regarding his appointment as the
Chief Business Officer of the Company during the Board meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On August 21, 2019, all of the Board members present
at the Meeting, except Dr. Tsung-Shann Jiang, reelected Dr. Tsung-Shann Jiang as the Chief Strategy Officer, effective since September
1, 2019 for a term of three years. Dr. Tsung-Shann Jiang excused himself from the discussion regarding his appointment as the Chief Strategy
Officer of the Company during the Board meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Security Ownership of Certain Beneficial Owners and Management</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The following table sets
forth certain information regarding beneficial ownership of our common stock as of April 20, 2022 (i) each person (or group of
affiliated persons) who is known by us to own more than five percent (5%) of the outstanding shares of our common stock, (ii) each
director, executive officer and director nominee, and (iii) all of our directors, executive officers and director nominees as a
group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Beneficial ownership is determined in accordance
with SEC rules and generally includes voting or investment power with respect to securities. For purposes of this table, a person or group
of persons is deemed to have&nbsp;&ldquo;beneficial ownership&rdquo;&nbsp;of any shares of common stock that such person has the right
to acquire within 60 days of the date of the respective table. For purposes of computing the percentage of outstanding shares of our common
stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60 days
of the date of the respective table is deemed to be outstanding for such person, but is not deemed to be outstanding for the purpose of
computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute
an admission of beneficial ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Unless otherwise noted, the business address of
each beneficial owner listed is&nbsp;44370 Old Warm Springs Blvd., Fremont, CA 94538. Except as otherwise indicated, the persons listed
below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent that power
may be shared with a spouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As of April 20, 2022, we
had&nbsp;30,307,329 shares of common stock issued and outstanding.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of
    Beneficial Owner</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount&#8239;and<BR>
    Nature of<BR> Beneficial<BR> Ownership</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent<BR>
    of Class</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Howard Doong</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,404</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eugene Jiang (1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">702,246</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chihliang An</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,334</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chi-Hsin (Richard) King</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">869</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yen-Hsin&nbsp;&nbsp;Chou</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,679</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Shin-Yu Miao (2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,865</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Tsang-Ming Jiang</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,067</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Ming-Fong Wu</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Norimi Sakamoto</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Tsung-Shann Jiang (3)(5)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,047,746</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39.8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Chang-Jen Jiang (4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,545</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoshinobu Odaira</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">163,702</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shih-Chen Tzeng</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Hwalin Lee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">106,550</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All officers and directors
    as a group (Fourteen (14) persons)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,141,674</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">YuanGene Corporation (5)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,296,968</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">less
than 1%.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
Jiang indirectly owns 673,189 shares of the Company&rsquo;s common stock through his ownership in AsianGene Corporation (controlled by
the controlling beneficiary of YuanGene Corporation) (&ldquo;AsianGene&rdquo;), 3,743 shares of the Company&rsquo;s common stock through
his ownership in BioFirst Corporation (controlled by the controlling beneficiary of YuanGene Corporation) (&ldquo;BioFirst&rdquo;), 141
shares of the Company&rsquo;s common stock through his ownership in Rgene Corporation (controlled by the controlling beneficiary of YuanGene
Corporation) (&ldquo;Rgene&rdquo;), and the rest of 25,173 shares through direct ownership.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Shin-Yu Miao held 1,192 shares of the Company&rsquo;s common stock through her ownership in BioFirst, 7 shares of the Company&rsquo;s
common stock through his ownership in Rgene, and the rest of 65,666 through direct ownership.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&nbsp;Tsung-Shann
Jiang owns &nbsp;2,296 shares of the Company&rsquo;s common stock through BioLite, Inc., 19,589 shares through Rgene, 96,364 shares through
BioFirst, 134,945 shares through his 20.2% ownership of Lion Arts Promotion Inc. (a shareholder of the Company) (&ldquo;Lion Arts&rdquo;),
1,675,988 through Lion Arts&rsquo; ownership of YuanGene Corporation, 509,878 shares through LionGene Corporation (shareholder of the
Company and controlled by the controlling beneficiary of YuanGene Corporation), 8,850 shares through Genepro Investment and the remaining
2,161,742 shares through direct ownership.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Chang-Jen Jiang held 939 shares of common stock in the Company through his ownership in BioFirst, 6 shares of the Company&rsquo;s common
stock through Rgene, and the rest of 4,600 shares through direct ownership.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YuanGene
Corporation is a company wholly-owned by Lion Arts, which is owned by Shuling Jiang (80%) and Dr.&nbsp;Tsung-Shann Jiang (20%); however,
YuanGene appointed Eugene Jiang to have sole voting control over the shares held by YuanGene, the principal office address of which is
2<SUP>nd</SUP>&nbsp;floor, Building B, SNPF Plaza, Savalalo, Apia, Samoa.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The New Director Nominees own the following shares
of our common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of Beneficial Owner</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
    and<BR> Nature of<BR> Beneficial<BR> Ownership</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Percent<BR>
                                            of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Class</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Che Wei Hsu</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,012</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shuling Jiang</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,438,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Kuang Tseng Chen</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,556</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All officers and directors,
    if all New Director Nominees elected, as a group (Fourteen (14) persons)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,041,692</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">less
than 1%.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Ms. Jiang owns 213,120 shares through Keypoint Technology Ltd.
(&ldquo;Keypoint&rdquo;), over which she has sole voting control and for which Eugene Jiang&rsquo;s mother is the chairman, 539,778 through
her 79.8% of Lion Arts, 6,620,979 through Lion Arts&rsquo; ownership of YuanGene Corporation and 64,215 shares directly.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Relationships and Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Except as disclosed herein, no director, executive
officer, shareholder holding at least 5% of shares of our common stock, or any family member thereof, had any material interest, direct
or indirect, in any transaction, or proposed transaction since January 1, 2020, in which the amount involved in the transaction exceeds
the lesser of $120,000 or one percent of the average of our total assets at the year-end for the last two completed fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Co-Development agreement with Rgene Corporation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On November 10, 2020, the Company and Rgene signed
an amendment to the Co-Dev Agreement dated May 26, 2017, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast
Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination
Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized.
Other provisions of the Co-Dev Agreement remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Collaborative agreement with BioFirst Corporation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On November 4, 2020, we executed an amendment
to our collaboration agreement with BioFirst dated July 24, 2017, to add BFC-1403 Intraocular Irrigation Solution and BFC-1404 Corneal
Storage Solution to our agreement. BFC-1404 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea
while BFC-1403 has broader utilization during a variety of ocular procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Initially ABVC will focus on BFC-1404, a solution
utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial keratoplasty
(back layer cornea transplant). Designated ABV-2002 under ABVC&rsquo;s product identification system, the solution is comprised of a specific
poly amino acid that protects ocular tissue from damage caused by external osmolarity exposure during pre-surgery storage. The specific
polymer in ABV 2002 can adjust osmolarity to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma
during the storage period. Stromal hydration results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea
swelling. ABV-2002 also contains an abundant phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial
properties and neuroprotection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can be
manufactured at lower cost. Categorized as a Class I Medical Device that has the lowest risk to patients, ABVC intends to submit a Premarket
Notification 510(K) submission to the FDA before the end of 2021 to demonstrate the device is at least as safe and effective as current
products on the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On May 11, 2018, the Company and BioFirst (Australia)
entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and
are due on demand prior to September 30, 2020. Afterwards, all outstanding load will bear interest rate at 12% per annum. On July 1, 2020,
the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation
based on co-development contract executed on July 24, 2017. The loan will be matured on September 30, 2021 with an interest rate of 6.5%
per annum. On September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project
needs. On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for
upcoming projects. The loan will mature on November 30, 2022 with an interest rate of 6.5% per annum. As of December 31, 2021 and 2020,
the aggregate amount of outstanding loan and accrued interest was $466,256 and $373,235, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Joint Venture Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On October 6, 2021 (the &ldquo;<B>Completion Date</B>&rdquo;),
the Company, Lucidaim Co., Ltd., a Japanese corporation (&ldquo;<B>Lucidaim</B>,&rdquo; together with the Company, the &ldquo;<B>Shareholders</B>&rdquo;),
and BioLite Japan K.K., a Japanese corporation (&ldquo;<B>Biolite JP&rdquo;</B>) entered into a Joint Venture Agreement (the &ldquo;<B>Agreement</B>&rdquo;).
Biolite JP is a private limited company (a Japanese&nbsp;<I>Kabushiki Kaisha</I>) incorporated on December 18, 2018 and at the date of
the Agreement has&nbsp;10,000&nbsp;ordinary shares authorized, with&nbsp;3,049&nbsp;ordinary shares issued and outstanding (the &ldquo;<B>Ordinary
Shares</B>&rdquo;). Immediately prior to the execution of the Agreement, Lucidaim owned&nbsp;1,501&nbsp;Ordinary Shares and the Company
owned 1,548&nbsp;Ordinary Shares. The Shareholders entered into the joint venture to formally reduce to writing their desire to invest
in and operate Biolite JP as a joint venture. The business of the joint venture shall be the research and development of drugs, medical
device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by Biolite JP
and its subsidiaries in Japan, or any other territory or businesses as may from time to time be agreed by an amendment to the Agreement.
The closing of the transaction is conditioned upon the approval and receipt of all necessary government approvals, which have been received.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Pursuant to the Agreement and the related share
transfer agreement, the Company shall transfer&nbsp;54&nbsp;of its Ordinary Shares to Lucidaim for no consideration, such that following
the transfer, Lucidaim shall own&nbsp;1,555&nbsp;Ordinary Shares (51%) and the Company shall own&nbsp;1,494&nbsp;Ordinary Shares (49%).
Also pursuant to the Agreement, there shall be 3 directors of Biolite JP, consisting of 1 director appointed by the Company and 2 appointed
by Lucidiam. The Company shall appoint Eugene Jiang, the Company&rsquo;s current Chairman and Chief Business Officer and Lucidaim shall
appoint Michihito Onishi; the current director of Biolite JP, Toru Seo (who is also a director of BioLite Japan&rsquo;s other shareholder),
is considered the second Lucidaim director. The Agreement further provides that the Company and Biolite JP shall assign the research collaboration
and license agreement between them to Biolite JP or prepare the same (the &ldquo;<B>License Agreement</B>&rdquo;). The aforementioned
transactions occurred on the Completion Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As per the Agreement, the Shareholders shall supervise
and manage the business and operations of Biolite JP. The directors shall not be entitled to any renumeration for their services as a
director and each Shareholder can remove and replace the director he/she/it appointed. If a Shareholder sells or disposes of all of its
Ordinary Shares, the director such Shareholder appointed must tender his/her resignation. The Agreement also sets forth certain corporate
actions that must be pre-approved by all Shareholders (the &ldquo;<B>Reserved Matters</B>&rdquo;). If the Shareholders are unable to make
a decision on any Reserved Matter, then either Shareholder can submit a deadlock notice to the other shareholder, 5 days after which they
must refer the matter to each Shareholder&rsquo;s chairman and use good faith to resolve the dispute. If such dispute is not resolved
within 10 days thereafter, then either Shareholder can offer to buy all of the other Shareholder&rsquo;s Ordinary Shares for cash at a
specified price; if there is not affirmative acceptance of the sale, the sale shall proceed as set forth in the sale offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Each of the Shareholders maintains a pre-emptive
right to purchase such number of additional Ordinary Shares as would allow such Shareholder to maintain its ownership percentage in Biolite
JP if Biolite JP issues any new Ordinary Shares. However, the Agreement provides that the Company shall lose its pre-emptive rights under
certain conditions. The Shareholders also maintain a right of first refusal if the other Shareholder receives an offer to buy such shareholder&rsquo;s
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Agreement also requires Biolite JP to obtain
a bank facility in the amount of JPY&nbsp;30,460,000&nbsp;(approximately USD272,000), for its initial working capital purposes. Pursuant
to the Agreement, each Shareholder agrees to guarantee such bank facility if the bank requires a guarantee. Accordingly, the Company may
be liable for the bank facility in an amount up to JPY&nbsp;14,925,400&nbsp;(approximately USD134,000), which represents&nbsp;49% of the
maximum bank facility. The Agreement further provides that Biolite JP shall issue annual dividends at the rate of at least&nbsp;1.5% of
Biolite JP&rsquo;s profits, if it has sufficient cash to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Pursuant to the Agreement, the Company and Biolite
JP agree to use their best efforts to execute the License Agreement by the end of December 2021<FONT STYLE="background-color: white">,
but since it was not yet executed, the parties continue such efforts</FONT>. The Company agreed that any negotiation on behalf of Biolite
JP regarding the terms of the License Agreement shall be handled by the directors appointed by Lucidaim. If the Company and such Lucidaim
directors do not reach agreement on the terms, Biolite JP may at its sole discretion determine not to execute the License Agreement without
any liability to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Agreement contains non-solicitation and non-compete
clauses for a period of 2 years after a Shareholder or its subsidiaries ceases to be a Shareholder, with such restrictive covenants limited
to business within the ophthalmologic filed or central neurological field. Any rights to intellectual property that arise from Biolite
JP&rsquo;s activities, shall belong to Biolite JP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Agreement contains standard indemnification
terms, except that no indemnifying party shall have any liability for an individual liability unless it exceeds JPY&nbsp;500,000&nbsp;(approximately
USD4,500) and until the aggregate amount of all liabilities exceeds JPY&nbsp;2,000,000&nbsp;(approximately USD18,000) and then only to
the extent such liability exceed such limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company paid $150,000&nbsp;towards the setup
of the joint venture; BioLite Japan&rsquo;s other shareholder also paid $150,000&nbsp;after the Letter of Intent was signed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Agreement shall continue for 10 years, unless
earlier terminated. The Agreement also allows a Shareholder to terminate the agreement upon certain defaults committed by another Shareholder,
as set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Agreement with BioLite, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We entered into a Collaborative Agreement with
BioLite, Inc., a company incorporated under the laws of Taiwan, and a subsidiary of the Company, (&ldquo;BioLite&rdquo;) on December 29,
2015, and then entered into two addendums to such agreement (as amended and revised, (the &ldquo;Agreement&rdquo;). The majority shareholder
of BioLite is one of the Company&rsquo;s subsidiaries, the Company&rsquo;s Chairman is a director of BioLite and Dr. Jiang, the Company&rsquo;s
Chief Strategy Officer and a director, is the Chairman of BioLite.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Pursuant to the Agreement, the Company acquired
the sole licensing rights to develop and commercialize for therapeutic purposes six compounds from BioLite. In accordance with the terms
of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity
securities owned by it at various stages on a schedule dictated by BioLite&rsquo;s achievements of certain milestones, as set forth in
the Agreement (the &ldquo;Milestone Payments&rdquo;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501
is approved for sale in the licensed territories. If BioLite fails to reach any of the milestones in a timely manner, it may not receive
the rest of the payments from the Company. According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone
Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &ldquo;December 2021 Payment&rdquo;)
and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&rsquo;s Board of Directors determined that the December
2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000,
that BioLite owes the Company as of December 31, 2021. On February 22, 2022, the parties entered into an amendment to the Agreement allowing
the Company to make all payments due under the Agreement via the forgiveness of debt, in equal value, owed by BioLite to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This was a related party transaction and was conducted
at arm&rsquo;s length. In addition to the Company&rsquo;s board of directors approving the modification of terms of the Agreement, the
Company&rsquo;s audit committee approved them too. The Board believes it is in the Company&rsquo;s best interest to cancel outstanding
debt and apply it to the December 2021 Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Following such approval, the Company and BioLite
entered into an amendment to the Agreement reflecting the modified payment method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other related party transactions&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due from related parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, there was an aggregate amount of $49,110 and $42,911 due from Rgene for working capital purposes, respectively.
Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date
was December 31, 2020. As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $33,520 and $31,684; and accrued
interest was $13,701 and $11,227, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with
Rgene, of which the amount due from Rgene was $1,889 for the year ended December 31, 2021.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,560, to meet its working capital
needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity
date was December 31, 2020. The loan was repaid in full during the year of 2021. &nbsp;&nbsp;As of December 31, 2021 and 2020, the outstanding
loan balance was $0 and $3,560, and accrued interest was $0 and $681, respectively.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 2, 2021, November 12, 2021 and December 20, 2021, the Company and BioFirst entered into loan agreements for a total amount of $45,000, $140,000, and $280,000, respectively, to meet its working capital needs. The loan will be matured on November 1, 2022, November 11, 2022, and December 19, 2022, respectively, all with an interest rate of 6.5% per annum. As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $465,000 and $0; and accrued interest was $3,435 and $0, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to mature on September 30, 2021 with an interest rate of 6.5% per annum, however, on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. &nbsp;&nbsp;On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will mature on November 30, 2022 with an interest rate of 6.5% per annum.&nbsp; As of December 31, 2021 and 2020, the aggregate amount of outstanding loan and accrued interest was $491,816 and $373,235, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &ldquo;BHK&rdquo;) entered into a co-development agreement, (the &ldquo;BHK
Co-Development Agreement&rdquo;, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term
of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2021 and 2020, due from BHK was $124,972 and $123,583,
respectively.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2021 and 2020, the outstanding advance balances was $675 and $675, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 31, 2020, the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of December 31, 2021 and 2020, the outstanding loan balance was $1,610 and $1,610, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to related parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
2019, BioFirst has advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent
to 12% per annum). As of December 31, 2021 and 2020, the aggregate amount of outstanding balance and accrued interest is $40,878 and
$23,647, respectively.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, BioFirst (Australia) has advanced the Company an aggregate amount of $132,443 and $0, respectively for
new project purpose.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, AsiaGene has advanced the Company an aggregate amount of $24,017 and $0, respectively for working capital
purpose. This advance bears 0% interest rate and is due on demand.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance
bears 0% interest rate and is due on demand.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2021 and 2020, the outstanding balance
due to the Jiangs amounted to $18,750 and $16,627, respectively. These loans bear interest rate of 0% to 1% per month, and are due on
demand.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
2018, the Company&rsquo;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate
from 12% to 13.6224% per annum. As of December 31, 2021 and 2020, the outstanding principal and accrued interest was $168,131 and $166,261,
respectively. Interest expenses in connection with these loans were $22,779 and $21,520 for the year ended December 31, 2021 and 2020,
respectively.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
January, 2020, the Company had advances from one employee for working capital purpose. The outstanding balance including accrued interest
due to this employee amounted to $0 and $72,705 as of December 31, 2021 and 2020, respectively. This loan bears interest rate of 1.5%
per annum, and the loan with interest has been repaid in full during the year ended December 31, 2021.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Promoters and Certain Control Persons</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">None of our management or other control persons
were &ldquo;promoters&rdquo; (within the meaning of Rule&nbsp;405 under the Securities Act), and none of such persons took the initiative
in the formation of our business or received any of our debt or equity securities or any of the proceeds from the sale of such securities
in exchange for the contribution of property or services, during the last five years.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROPOSAL NO. 3&nbsp;&mdash;&nbsp;RATIFICATION
OF SELECTION OF INDEPENDENT REGISTERED PUBLIC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Audit Committee has selected KCCW ACCOUNTACY CORP. to serve as the independent registered public accounting firm of the Company for the
fiscal year ending December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are asking our Shareholders to ratify the selection of KCCW as our independent registered public accounting firm. In the event our Shareholders
fail to ratify the appointment, the Audit Committee may reconsider this appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have been advised by KCCW that neither the firm nor any of its associates had any relationship during the last fiscal year with our company
other than the usual relationship that exists between independent registered public accountant firms and their clients.&nbsp;&nbsp;Representatives
of KCCW are not expected to attend the Meeting virtually and therefore are not expected to be available to respond to any questions.&nbsp;&nbsp;As
a result, representatives of KCCW will not make a statement during the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Principal Accountant
Fees and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Various audit, audit related and non-audit services to us is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Audit Fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">249,350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">280,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit Related Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">All Other Fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total Fees</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">328,100</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">280,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Audit Fees. &nbsp;&nbsp;Audit Fees consists of
fees for professional services rendered by our principal accountants for the contemporaneous audit of our annual financial statements
and the review of quarterly financial statements or services that are normally provided by our principal accountants in connection with
statutory and regulatory filings or engagements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Audit Related Fees. &nbsp;&nbsp;Audit Related
Fees consists of fees for assurance and related services by our principal accountants that are reasonably related to the performance of
the audit or review of our financial statements and are not reported under &ldquo;Audit Fees.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Tax Fees and All Other Fees. &nbsp;&nbsp;Tax Fees
and All Other Fees Consists of fees for products and services provided by our principal accountants, other than the services reported
under &ldquo;Audit Fees,&rdquo; &ldquo;Audit-Related Fees&rdquo; and &ldquo;Tax Fees&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The policy of our audit committee
and our board of directors is to pre-approve all audit and non-audit services provided by our principal auditors, including audit services,
audit-related services, and other services as described above, other than those for de minimis services which are approved by the audit
committee or our board of directors prior to the completion of the services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Policies and Procedures Relating to Approval of Services by Our
Independent Registered Public Accountants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Audit Committee is solely responsible for the approval in advance of all audit and permitted non-audit services to be provided by our
independent registered public accounting firms (including the fees and other terms thereof), subject to the&nbsp;<I>de minimus&nbsp;</I>exceptions
for non-audit services provided by Section 10A(i)(1)(B) of the Exchange Act, which services are subsequently approved by the Audit Committee
prior to the completion of the audit. None of the fees listed above are for services rendered pursuant to such&nbsp;<I>de minimus</I>&nbsp;exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Audit Committee of our Board of Directors has established its pre-approval&nbsp;policies&nbsp;and procedures, pursuant to which the Audit
Committee approved the foregoing audit, tax and non-audit services provided by KCCW in 2021. Consistent with the Audit Committee&rsquo;s
responsibility for engaging our independent auditors, all audit and permitted non-audit services require pre-approval by the Audit Committee.
The full Audit Committee approves proposed services and fee estimates for these services. One or more independent directors serving on
the Audit Committee may be delegated by the full Audit Committee to pre-approve any audit and non-audit services. Any such delegation
shall be presented to the full Audit Committee at its next scheduled meeting. Pursuant to these procedures, the Audit Committee approved
the foregoing audit services provided by KCCW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vote Required</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal&nbsp;No. 3 will be
approved if a majority of the total votes properly cast in person or by proxy at the Meeting by the holders of Common Stock vote &ldquo;FOR&rdquo;
the proposal. Abstentions and broker non-votes will have no effect on the result of the vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recommendation of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The Board unanimously
recommends that you vote all of your shares &ldquo;FOR&rdquo; the ratification of KCCW as independent registered public accountants as
described in this Proposal&nbsp;No. 3.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL NO. 4 &mdash; ADVISORY VOTE ON EXECUTIVE
COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
SEC has adopted final rules requiring public companies to provide stockholders with periodic advisory (non-binding) votes on executive
compensation, also referred to as &ldquo;say-on-pay&rdquo; proposals. We are presenting the following proposal, which gives you as a stockholder
the opportunity to endorse or not endorse the compensation paid to our Principal Executive Officer and Principal Financial Officer (collectively,
the &ldquo;<B>Named Executive Officers</B>&rdquo;), as disclosed in this Proxy Statement pursuant to Item 402 of Regulation S-K (including
the compensation tables and accompanying narrative discussion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify; background-color: white"><B>&ldquo;RESOLVED, that the compensation
paid to the Company&rsquo;s Named Executive Officers for the year ended December 31, 2021, as disclosed pursuant to Item 402 of Regulation
S-K, compensation tables and narrative discussion is hereby APPROVED.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Exchange Act and the rules promulgated thereunder, this vote will not be binding on the Board or the Compensation Committee and
may not be construed as overruling a decision by the Board or the Compensation Committee, creating or implying any change to the fiduciary
duties of the Board or the Compensation Committee or any additional fiduciary duty by the Board or the Compensation Committee or restricting
or limiting the ability of stockholders to make proposals for inclusion in proxy materials related to executive compensation.&nbsp;&nbsp;The
Board and the Compensation Committee, however, may in their discretion take into account the outcome of the vote when considering future
executive compensation arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vote Required</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal&nbsp;No. 4 will be
approved if a majority of the total votes properly cast in person or by proxy at the Meeting by the holders of Common Stock vote &ldquo;FOR&rdquo;
the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recommendation of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The Board unanimously
recommends that you vote all of your shares &ldquo;FOR&rdquo; the compensation of the Company&rsquo;s named executive officer as described
in this Proposal&nbsp;No. 4.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROPOSAL NO. 5
&mdash; ADVISORY VOTE ON FREQUENCY OF ADVISORY VOTES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ON EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
SEC has also adopted final rules requiring public companies to hold an advisory (non-binding) vote on the frequency of holding say-on-pay
votes. Accordingly, as required by the SEC&rsquo;s rules, we are including this proposal to give our shareholders the opportunity to inform
us as to how often they wish the Company to include a say-on-pay proposal, similar to Proposal No. 4, in our future proxy statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are presenting the following proposal, which gives you, as a shareholder, the opportunity to inform us as to whether you wish us to hold
an advisory (non-binding) vote on executive compensation once every (1) one year, (2) two years, or (3) three years, or you may abstain
from voting on the proposal set forth in the following resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><B>&ldquo;RESOLVED,
that the shareholders determine, on an advisory basis, whether the preferred frequency of an advisory vote on the executive compensation
of the Company&rsquo;s Named Executive Officers as set forth in the Company&rsquo;s Proxy Statement for the 2022 Annual Meeting of Shareholders
should be every year, every two years, or every three years.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Board recommends that you vote for every three (3) years as the desired frequency for the Company to hold a non-binding, advisory vote
of the shareholders on executive compensation. We believe this frequency is appropriate for the reasons set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Our equity compensation program is designed to support long-term
value creation, and a vote every three years will allow the shareholders to better judge the equity compensation program in relation
to our long-term performance. We strive to ensure management&rsquo;s interests are aligned with shareholders&rsquo; interests to support
long-term value creation through our equity compensation program. To that end, we may grant equity awards to vest over multi-year periods
of service to encourage our Named Executive Officers to focus on long-term performance, and recommend a vote every three years, which
would allow the equity compensation to be evaluated over a similar time-frame and in relation to long-term performance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">A vote every three (3) years will provide the Board and the Compensation
Committee with the time to thoughtfully consider and thoroughly respond to shareholders&rsquo; sentiments and to implement any necessary
changes in light of the timing required therefor. The Board and the Compensation Committee will carefully review changes to the executive
compensation to maintain the effectiveness and credibility of the program, which is important for aligning interests and for motivating
and retaining our Named Executive Officers.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">We are open to input from shareholders regarding board and governance
matters, as well as the equity compensation program. We believe that the shareholders&rsquo; ability to contact us and the Board at any
time to express specific views on executive compensation holds us accountable to shareholders and reduces the need for and value of more
frequent advisory votes on executive compensation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Exchange Act and the rules promulgated thereunder, this vote on the frequency of future advisory votes on named executive officer
compensation is non-binding on the Board and its committees. This vote may not be construed as overruling a decision by the Board or its
committees, creating or implying any change to the fiduciary duties of the Board or its committees or any additional fiduciary duty by
the Board or its committees or restricting or limiting the ability of shareholders to make proposals for inclusion in proxy materials
related to executive compensation. Notwithstanding the Board&rsquo;s recommendation and the outcome of the vote on this matter, the Board
may, in the future, decide to conduct advisory votes on a more or less frequent basis and may vary its practice based on factors such
as discussions with shareholders and the adoption of material changes to compensation programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Vote Required</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Approval
of this proposal will require the affirmative vote of the holders of a majority of the shares of the Company&rsquo;s Common Stock represented
in person or by proxy and entitled to vote at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recommendation of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The Board recommends
that shareholders vote to have the non-binding vote on executive compensation occur every three years.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board knows of no other
matter to be presented at the Meeting. If any additional matter should properly come before the Meeting, it is the intention of the persons
named in the enclosed proxy to vote such proxy in accordance with their judgment on any such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Electronic&nbsp;Delivery Of&nbsp;Future&nbsp;Shareholder Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Registered shareholders can
further save the Company expense by consenting to receive all future proxy statements, forms of proxy and annual reports electronically
via e-mail or the Internet. To sign up for electronic delivery, please access the website www.proxyvote.com when transmitting your voting
instructions and, when prompted, indicate that you agree to receive or access shareholder communications electronically in future years.
Your choice will remain in effect unless and until you revoke it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To revoke your decision to
receive or access shareholder communications electronically, access the website www.proxyvote.com, enter your current PIN, select &ldquo;Cancel
my Enrollment&rdquo; and click on the Submit button. After submitting your entry, the Cancel Enrollment Confirmation screen will be displayed.
This screen will show your current Enrollment Number. To confirm your enrollment cancellation, click on the Submit button. Otherwise,
click on the Back button to return to the Enrollment Maintenance screen. After submitting your entry, the Cancel Enrollment Complete screen
will be displayed. This screen will indicate that your enrollment has been cancelled. You may be asked to complete a brief survey to help
us understand why you opted out of electronic delivery. You will be sent an e-mail message confirming the cancellation of your enrollment.
No further electronic communications will be conducted for your account and your Enrollment Number will be marked as &ldquo;Inactive.&rdquo;
You may at any time reactivate your enrollment. You will be responsible for any fees or charges that you would typically pay for access
to the Internet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Deadline for Submission of Shareholder Proposals
for 2023 Annual Meeting of Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For any proposal to be considered
for inclusion in our proxy statement and form of proxy for submission to the Shareholders at our 2023 Annual Meeting of Shareholders,
it must be submitted in writing and comply with the requirements of Rule 14a-8 of the Exchange Act. Such proposals must be received by
the Company at its offices 44370 Old Warm Springs Blvd., Fremont, CA 94538, Attention: Chief Executive Officer, no later than November
1, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are not notified of
a Shareholder proposal a reasonable time prior to the time we send our proxy statement for our 2023 annual meeting, then our Board will
have discretionary authority to vote on the Shareholder proposal, even though the Shareholder proposal is not discussed in the proxy statement.
In order to curtail any controversy as to the date on which a Shareholder proposal was received by us, it is suggested that Shareholder
proposals be submitted by certified mail, return receipt requested, and be addressed to ABVC BioPharma, Inc., 44370 Old Warm Springs Blvd.,
Fremont, CA 94538 Attention: Chief Executive Officer. Notwithstanding, the foregoing shall not effectuate any rights of Shareholders to
request inclusion of proposals in our proxy statement pursuant to Rule 14a-8 under the Exchange Act nor grant any Shareholder a right
to have any nominee included in our proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Proxy Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The solicitation of proxies
is made on behalf of the Board and we will bear the cost of soliciting proxies.&nbsp;&nbsp;Proxies may be solicited through the mail and
through telephonic or telegraphic communications to, or by meetings with, Shareholders or their representatives by our directors, officers
and other employees who will receive no additional compensation therefor. We may also retain a proxy solicitation firm to assist us in
obtaining proxies by mail, facsimile or email from record and beneficial holders of shares for the Meeting. If we retain a proxy solicitation
firm, we expect to pay such firm reasonable and customary compensation for its services, including out-of-pocket expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We request persons such as
brokers, nominees and fiduciaries holding stock in their names for others, or holding stock for others who have the right to give voting
instructions, to forward proxy material to their principals and to request authority for the execution of the proxy.&nbsp;&nbsp;We will
reimburse such persons for their reasonable expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Annual Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Annual Report is being
sent with this Proxy Statement to each Shareholder and is available at&nbsp;<U STYLE="text-decoration: none">www.proxyvote.com</U>&nbsp;as well as on the SEC&rsquo;s
website at www.sec.gov.&nbsp;&nbsp;The Annual Report contains our audited financial statements for the fiscal year ended December 31,
2021.&nbsp;&nbsp;The Annual Report, however, is not to be regarded as part of the proxy soliciting material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Delivery of Proxy
Materials to Households</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only one copy of this proxy
statement and one copy of our Annual Report are being delivered to multiple registered Shareholders who share an address unless we have
received contrary instructions from one or more of the Shareholders. A separate form of proxy and a separate notice of the Meeting are
being included for each account at the shared address. Registered Shareholders who share an address and would like to receive a separate
copy of our Annual Report and/or a separate copy of this proxy statement, or have questions regarding the householding process, may contact
the Company&rsquo;s transfer agent: Vstock Transfer, LLC, by calling (212) 828-8436, or by forwarding a written request addressed to Vstock
Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.&nbsp;Promptly upon request, a separate copy of our Annual Report on Form&nbsp;10-K
and/or a separate copy of this proxy Statement will be sent. By contacting Vstock Transfer, LLC, registered Shareholders sharing an address
can also (i)&nbsp;notify the Company that the registered Shareholders wish to receive separate annual reports to Shareholders, proxy statements
and/or Notices of Internet Availability of Proxy Materials, as applicable, in the future or (ii)&nbsp;request delivery of a single copy
of annual reports to Shareholders and proxy statements in the future if registered Shareholders at the shared address are receiving multiple
copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many brokers, brokerage firms,
broker/dealers, banks and other holders of record have also instituted &ldquo;householding&rdquo; (delivery of one copy of materials to
multiple Shareholders who share an address). If your family has one or more &ldquo;street name&rdquo; accounts under which you beneficially
own shares of our Common Stock, you may have received householding information from your broker, brokerage firm, broker/dealer, bank or
other nominee in the past. Please contact the holder of record directly if you have questions, require additional copies of this proxy
statement or our Annual Report or wish to revoke your decision to household and thereby receive multiple copies. You should also contact
the holder of record if you wish to institute householding.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Where You Can Find Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accompanying this proxy statement
is a copy of the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2021. Such Report constitutes the Company&rsquo;s
Annual Report to its Shareholders for purposes of Rule 14a-3 under the Exchange Act. Such Report includes the Company&rsquo;s audited
financial statements for the 2021 fiscal year and certain other financial information, which is incorporated by reference herein. The
Company is subject to the informational requirements of the Exchange Act and in accordance therewith files reports, proxy statements and
other information with the SEC. Such reports, proxy statements and other information are available on the SEC&rsquo;s website at&nbsp;<I>www.sec.gov</I>.
Shareholders who have questions in regard to any aspect of the matters discussed in this proxy statement should contact Chihliang An,
our Chief Financial Officer, at info@ambrivis.com or by telephone at 510-668-0881.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea158566ex99-2_abvcbio.htm
<DESCRIPTION>FORM OF PROXY CARD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Proxy Card</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ABVC BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>May 20, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>To Be Held at 9:00 a.m. EST on May 20, 2022
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Record Date &ndash; April 20, 2022)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD
OF DIRECTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby appoints Howard Doong,
as proxy of the undersigned, with full power to appoint his substitute, and hereby authorizes him to represent and to vote all the shares
of stock of ABVC BioPharma, Inc. which the undersigned is entitled to vote, as specified below on this card, at the Annual Meeting of
Shareholders of ABVC BioPharma, Inc. to be held virtually on Zoom on May 20, 2022, at 9:00 a.m., EST, and at any adjournment or postponement
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">To attend the virtual Meeting via Zoom,
go to: </FONT>https://us06web.zoom.us/webinar/register/WN_N4Og75-7SC-D69RZENZRMg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE
VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED IN ACCORDANCE WITH
THE RECOMMENDATION OF THE BOARD OF DIRECTORS FOR EACH OF THE PROPOSALS.</B> This proxy authorizes the above designated proxy to vote in
his discretion on such other business as may properly come before the meeting or any adjournments or postponements thereof to the extent
authorized by Rule 14a-4(c) promulgated under the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">THE BOARD OF DIRECTORS
UNANIMOUSLY RECOMMENDS THAT YOU VOTE &ldquo;<B>FOR ALL</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">OF PROPOSAL 1 AND PROPOSAL
2 AND &ldquo;<B>FOR</B>&rdquo;&nbsp;OF PROPOSALS 3 AND 4 AND &ldquo;THREE YEARS&rdquo; FOR PROPOSAL 5 SET FORTH BELOW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">PLEASE SIGN, DATE AND
RETURN PROMPTLY, <U>BEFORE 11:59 P.M. EST ON MAY 19, 2022</U>, IN THE ENCLOSED ENVELOPE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">PLEASE MARK YOUR VOTE
IN BLUE OR BLACK INK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROPOSAL 1: </B>To re-elect the nominees listed in the Proxy Statement
to the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOMINEES:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang</FONT></TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. T.S. Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tsang Ming Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norimi Sakamoto</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yen-Hsin Chou</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chang-Jen Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Shin-Yu Miao</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoshinobu Odaira</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08&nbsp;&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For All</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Withhold All</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For All Except</B></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 120px; padding-right: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>INSTRUCTION</I>:</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To withhold authority to vote for any individual nominee(s), mark <B>&ldquo;FOR ALL EXCEPT&rdquo; </B>and fill in the box next to each nominee you wish to withhold, as shown here: </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 120px; padding-right: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 192px; padding-right: 0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROPOSAL 2: </B>To elect the nominees listed in the Proxy Statement
to the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOMINEES:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Che Wei Hsu</FONT></TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuling Jiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuang-Tseng Chen</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03&nbsp;&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For All</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Withhold All</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For All Except</B></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 120px; padding-right: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>INSTRUCTION</I>:</FONT></TD>
    <TD STYLE="padding-top: 0; text-align: justify; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To withhold authority to vote for any individual nominee(s), mark <B>&ldquo;FOR ALL EXCEPT&rdquo; </B>and fill in the box next to each nominee you wish to withhold, as shown here: </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-top: 0; width: 120px; padding-right: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-top: 0; width: 192px; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROPOSAL 3: </B>To ratify the selection of
KCCW ACCOUNTACY CORP. as the Company&rsquo;s independent registered public accounting firm for year ending December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Against</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abstain</B></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.7pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROPOSAL 4: </B>To approve, by a non-binding
vote, the Company&rsquo;s executive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Against</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abstain</B></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROPOSAL 5: </B>To approve, by a non-binding
vote, the frequency of future Stockholder advisory votes relating to the Company&rsquo;s executive compensation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1 Year</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2 Years</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3 Years</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abstain</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.7pt 0pt 0; text-align: justify">Please indicate if you intend to attend
this meeting&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744; YES&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;
NO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Shareholder:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 25%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 21%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 28%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name shares held in (Please print):</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account Number (if any):</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No. of Shares Entitled to Vote:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Certificate Number(s):&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note:</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign exactly as your name or names appear in the Company&rsquo;s stock transfer books. When shares are held jointly, each holder should
sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">If the signer is a corporation,
please sign full corporate name by duly authorized officer, giving full title as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">If the signer is a partnership,
please sign in partnership name by authorized person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">Please provide any change of address
information in the spaces below in order that we may update our records:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 240px; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P></BODY> </HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>abvc-20220427.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qA5s7xRiXgen8uKa3EsWaeEuaPtzplyiZlBtmd5bal6fyEidyqplyn9tHJ20cIA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ABVC="http://abvcpharma.com/20220427" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20220427">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220427_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220427_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>abvc-20220427_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>abvc-20220427_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20220427.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139683183806888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 27,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-91436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>ea158566-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20220427.xsd" xlink:type="simple"/>
    <context id="From2022-04-27to2022-04-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-04-27</startDate>
            <endDate>2022-04-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-27to2022-04-27">0001173313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-27to2022-04-27">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-04-27to2022-04-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-27to2022-04-27">2022-04-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-04-27to2022-04-27">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-04-27to2022-04-27">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-04-27to2022-04-27">333-91436</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-04-27to2022-04-27">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-27to2022-04-27">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-27to2022-04-27">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-04-27to2022-04-27">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-27to2022-04-27">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-04-27to2022-04-27">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-04-27to2022-04-27">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-04-27to2022-04-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-04-27to2022-04-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-04-27to2022-04-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-04-27to2022-04-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-04-27to2022-04-27">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-27to2022-04-27">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-27to2022-04-27">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-04-27to2022-04-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( !-(FU27BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ $TB;5*K$(A8S 0
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M6N=6RKV'5[+E&''\GN4/4$L#!!0    ( !-(FU0D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  32)M499!YDAD!  #/ P
M$P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=
M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'
M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-
MF<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*
M1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP
MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,
M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    (
M !-(FU0'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ $TB;5%M?U2#O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ $TB;5)E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  32)M4_B1#OCH$   X$   &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ $TB;5)^@&_"Q
M @  X@P   T              ( !?@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    "  32)M4EXJ[',     3 @  "P              @ %:#P  7W)E;',O
M+G)E;'-02P$"% ,4    "  32)M4JL0B%C,!   B @  #P
M@ %#$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ $TB;5"0>FZ*M
M^ $  !H              ( !HQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ $TB;5&60>9(9 0  SP,  !,              ( !
MB!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  TA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea158566-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea158566-8k_abvcbio.htm">ea158566-8k_abvcbio.htm</File>
    <File>abvc-20220427.xsd</File>
    <File>abvc-20220427_lab.xml</File>
    <File>abvc-20220427_pre.xml</File>
    <File>ea158566ex99-1_abvcbio.htm</File>
    <File>ea158566ex99-2_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea158566-8k_abvcbio.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea158566-8k_abvcbio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20220427_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20220427_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abvc-20220427.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20220427",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea158566-8k_abvcbio.htm",
      "contextRef": "From2022-04-27to2022-04-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abvcpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea158566-8k_abvcbio.htm",
      "contextRef": "From2022-04-27to2022-04-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-22-021801-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-021801-xbrl.zip
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M?E6OJ&#$&->%KKLMMQA;'!-=R=KPIF&NO"XXQ=]U], L=(MM4C=NI\WUH+
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M(^T:G<J6H%YCIN_RH!+Q><*4F*49[E@DRY3B)3V.O6]F]9N_VZ44K.Q"S&_
M7Q1'^5_$H8%L+HV&DVGJY1]02P,$%     @ $TB;5#QB>.[_"@  ;(<  !4
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MR;E!109(YN"-NHLX%@<K*_]<)Y1,P6-@U;HEK,-NDRN+,"":8'< 0Z7R@_Z
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M>_\NL2LP^@UK0&!E$*#TVC.!$0'CJ!:!5 @J8ORC,\^R+>%O L@2X@DCT#P
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MO&:QEGZXSM]F'LW//CO^'U!+ P04    "  32)M4.BGZKFZL  ".GP4 &@
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M-\HE3SQ7X8F&!.U*P0<<16Z(^MT1IZ1I,T'?R(DABB@H17K%AO(-IKU:(>$
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MA;VN[.;X&HC78"'#_7>,7C?L*=^>;_0VPGBCX>C6<BBV@<MPA=H2C>[9.#:
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MHQ9-?B&>YB$)XYXWZB/;"=)*U,7SW1 T":ECQ]:>Q>HR2VT$LPV/&3C\C62
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M.KE)X!J/X<XFL[Q:,:GEI8I:P:&0BDI-_4PPK!I%4[9(LH) \"K$7L4_6GY
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M&#9_N_I*=AYH+^>33^P^$\7IB^RZK9KXVD,XJ>^W!O3#F+Y.H!!*(:Y6R-K
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M44(=D:30K9A!O,CIP@U"WL%V!A*)..K9$;MMFWY+[EWP:%WCTCK<#0RT+-C
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M9W8WL@9S&HEX+H'(TB-^TJCF?"F*&U-Z>J1B3*(*8VI4KW>Q#OK#]#?U:!W
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M9_R-4R9K0H C;7^;-E:I[]^3(?8?M%'UBA<AF_H#SA_-$HM2Z#FD E;#4+7
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MXY[>,KT.WN-5Y>(N%_?+7=S9]DF 3^Y=3R%25,RMT5,/',.;$6)'846\'U$
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M_)]=9^=XQ]D_VF40TM1@ ^,-#)VP[49H>Z/9@J[23K4R@)?1R!>TYRQ)7JZ
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ML*&_P@ -3@+^K9]@5A4 E>WLOC9'O>$PIJ?@0@FMRX#3=^$G?))NMW/0="Z
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MHT@G?'83!3?P>TDJM%^C 'AJF'!%$@H!SM!]!<S%;3:;N'P$!#;E>)C.+?2
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M,D^Z146$;Q?DJ8IO_$3Q+<(VV*MN:0BY9J%3&O*;Y(O(N0"_-(SP]E'5\=.
M@XJ(7D FV43>H_.?0)U)< ,#EK@87S*< AW5'F";M6URX<.E1S=*1"/'C5-K
M%\Y8_9+ __MISDU /\2XGOVF1&&@A\/,F$>6:/G*O+U>*S%)M[@(,7+[?3EC
MFV! #EW^F#SG)[\@T<42ML2@4(DNB1]0CAC !,R9@:0R&FT=KD:0FBB67M]7
M%#1DL2^J".R]<,,EBOJH$-*4'92F)7N(X#.'(DB?62A!%,"-+[@54 $'E-WB
M1)R75WHOP2G4<>+RW9D R%!YPP!;[@&R^*SEXOIS/,]U>F",S& SZ+_.L_A
M^R9 Q&HDR#ZAY2E&7<*:7!+8$B #[G(=14-GY)$5B5D("68$RD4GTPSX! *&
M[EH^0 Z.^"W/ MN16&FKR?LD&4F;70Z):#3BW?:SF<:[' )5NR]+;22A@9>,
MT6;#B"C'BA7% ="MY(]$8,N6/9!Q<'J.^W#T%?U(LF[B!=*5#?\EE$SY$AP)
M PP5!)7 ,#U&IWC!S/0,42FJH T=RF;;7.VIR91S:*EZAN(7&8A*]($3^@#K
MZW,2*78007+&'D5E Q.#0EG \8S;>1YCA_91_\S3OB43%9DWM[]$!EVOH??
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M*+*JX$D>8&J#K@HH/,X!#T8:3!4 19Q4H0$8::&'3FN)WY!$,R:VE6X93<=
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ME6ER''"D'4V+W.:3M*SYJG3MI(R]J<I2K( 3YRJ(OJ]$..C]28Q-2% 'PL(
M$>B7%" R299D[1A)O6#'$CCR9@95=OQ=!S1!,(>I9X8WX_0M> V[1U^UFDU\
M(*",J%!B6AC]A;.G9?*D\E'ZHEY+U""+V6XQDX\PNIA2Z6^4D>EVK:BB"2A^
M,%;#C%PO@]03F6-HW-C @+0WRFQ12RQS@,0M1\/*29(V ;\WY[Z4<QMN0@6.
M/L#&<^)HY@7I3,,&SX?ED)&T6@EA,8RV&9<7IMWEW0END?=PWX-FBS)$3%@8
M;Y_B="(W)4MC:++>?'2SG^=D/?+\(.%8*/FU0@/^' #DXJ9<.&SNXH4A^CT
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M8US)$FR257@?;4I]]3%?6V=FKX2(F'.-!S!C>_T86\=A!5S#KD/YJ">LD$'
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MH6Y3/F0P#_M3G%R\_H<:5?SYZ?V[W_\_4$L#!!0    ( !-(FU022!<2Q0P
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M+IN)Q::40HDMN4TBG>A-D!.Z,\<PR[<: ?L(C C(6FUE6R3M379R2P3K8Q[
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M   1              "  0    !A8G9C+3(P,C(P-#(W+GAS9%!+ 0(4 Q0
M   ( !-(FU0\8GCN_PH  &R'   5              "  6@#  !A8G9C+3(P
M,C(P-#(W7VQA8BYX;6Q02P$"% ,4    "  32)M4S' P8U4'  #%6   %0
M            @ &:#@  86)V8RTR,#(R,#0R-U]P<F4N>&UL4$L! A0#%
M  @ $TB;5!/887[I$P  67   !<              ( !(A8  &5A,34X-38V
M+3AK7V%B=F-B:6\N:'1M4$L! A0#%     @ $TB;5#HI^JYNK   CI\% !H
M             ( !0"H  &5A,34X-38V97@Y.2TQ7V%B=F-B:6\N:'1M4$L!
M A0#%     @ $TB;5!)(%Q+%#   86X  !H              ( !YM8  &5A
M,34X-38V97@Y.2TR7V%B=F-B:6\N:'1M4$L%!@     &  8 F@$  ./C
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
